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Balancing diets for lysine (Lys) and methionine (Met) in dairy rations is becoming a 
regular practice in today’s industry. In order to be able to use rumen-protected AA (RPAA) in 
those diets a method to assess the efficacy and bioavailability needs to be proposed. The 
objective of the following studies was to propose the acceptance of the plasma free AA dose-
response technique as a standardized methodology for evaluating RPAA in lactating dairy cows. 
Thirteen dose-response Latin square studies using ruminally-cannulated multiparous Holstein 
cows were conducted. Regression analysis of the slopes against the difference between plasma 
Lys concentration of basal and highest infusion amount, plasma Lys concentration at highest 
infusion amount, basal plasma Lys concentration, days in milk, milk yield, milk true protein 
concentration and yield, and dry matter intake, indicated the factor that most affected the 
magnitude of the slope, and hence the technique’s precision, was the difference between plasma 
Lys concentration of basal and highest infusion amount. It was concluded that the plasma free 
AA dose-response technique is sensitive to increasing amounts of absorbed Lys, and therefore is 
an appropriate technique for evaluating RP-Lys supplements.  
The objectives of the second study were: 1) to confirm linearity in plasma Met response 
by infusion or rumen protected Met (RP-Met) from Smartamine® M ( Adisseo, Alpharetta, GA) 
 xii 
 
2) to determine if using the plasma concentration of Met or total sulfur AA (TSAA) expressed in 
micromolar basis is the more accurate response parameter, and 3) to determine if expressing the 
plasma concentrations of Met and TSAA as percentages of total AA concentration (subtracted 
from Met or TSAA concentration, respectively) would reduce the variability of estimating Met 
bioavailability. Ten rumen-cannulated Holstein cows were fed a Met-deficient basal diet and 
assigned to a replicated 5 × 5 Latin square design with 7-d experimental periods. Treatments 
were 0, 12, and 24 g/d of abomasally infused Met and 15 and 30 g/d of fed Met from a RP-Met 
supplement. Slopes for infused and fed Met were 1.40 and 1.04 for plasma Met expressed on a 
micromolar basis, and 0.066 and 0.049 for plasma Met expressed as a percentage of total AA. 
Corresponding values for plasma TSAA were 2.00 and 1.64 on a micromolar basis, and 0.104 
and 0.084 when expressed as a percentage of total AA. Estimates of bioavailability for the RP-
Met supplement ranged from 74.4 to 81.8%.  We conclude that the plasma free AA dose-
response technique is precise, and as Met is a precursor to other sulfur AA, the concentration of 
TSAA expressed as a percentage of total AA should be used when calculation bioavailability of 
RP-Met products.  
Determination of bioavailability for RPAA using the plasma free AA dose-response 
method has relied on blood sampling 2, 4, 6, and 8 h after the morning feeding the last 3 d of 
each period in Latin square experiments with cows fed every 8 h. The objective of the third study 
was to determine if this sampling protocol captured the diurnal variation in plasma Met 
concentrations that exists and adequately measures the bioavailability of Met in a RP Met 
supplement Smartamine M. Five multiparous lactating Holstein cows were used in a 5 × 5 square 
design with 7-d periods. Treatments were 0, 12, and 24 g/d of abomasally infused Met and 15 
and 30 g/d of fed Met from a RP-Met. Blood samples were collected via jugular catheters every 
 xiii 
 
2 h starting at 0700 h on d 5, 6, and 7 of each period. There was no diurnal variation in plasma 
Met concentrations (P = 0.18). Plasma Met concentrations were averaged across days for the 2-8, 
10-16, 18-24, and 2-24 h blood sampling periods. The bioavailabilities of Met in RP-Met 
averaged 84.7, 84.4, 90.0, and 84.6% for the 2-8, 10-16, 18-24, and 2-24 h sampling periods, 
respectively. The similarity in estimates of bioavailability for RP-Met for the 2-8 and 2-24 h 
sampling periods indicates that our original blood sampling protocol (i.e., 2-8 h) is adequate for 
determining the bioavailability of RP-Met. 
 The objective of the fourth study was to use the plasma free AA dose-response 
method to compare the bioavailability of Met in Smartamine M (Adisseo, Antony, France) from 
the new (SM1) and original (SM2) production plants along with 2 additional commercially 
available RP-Met products, Mepron (MPN; Evonik Ind., Kennesaw, GA) and AminoShure-M 
(ASM; Balchem Corp., New Hampton, NY). Ten multiparous lactating Holstein cows, fed Met-
deficient diets, were used in a replicated 5 × 5 Latin square design with 7-d periods. Treatments 
included a negative control with no added RP-Met (CON) or 30 g of Met supplied by the 4 RP-
Met products. Plasma total sulfur AA concentrations (µM) were greatest for cows fed SM1 and 
SM2 and intermediate for MPN and ASM compared to CON. Based on the published 
bioavailability of Met in SM2 (80%), the calculated bioavailabilities of Met in SM1, MPN, and 







REVIEW OF LITERATURE 
Introduction 
For most lactating and transition diets fed to dairy cows in the United States Met and Lys are the 
2 most limiting amino acids (AA) involved in protein synthesis with Met also acting as a methyl 
donor. These 2 AA cannot be synthesized by mammals, but are synthesized from aspartate by 
plants and microorganisms. When catabolized, Met and Lys enter the Krebs cycle as acetyl CoA 
and succinyl CoA, respectively. 
 While more lactating dairy cow diets are being formulated to balance for these 2 AA, it is 
difficult to meet requirements without over feeding protein (NRC, 2001). This results in excess 
N and protein being excreted in urine and feces by the animal, which increases N output to the 
environment. One way to formulate dairy diets without overfeeding protein is to use rumen-
protected AA (RPAA). There are different ways to protect AA, but a particular RPAA should 
meet the following criteria: 1) the coating needs to protect the AA from degradation by ruminal 
microorganisms, 2) the coating needs to release the AA either in the abomasum or small 
intestine, and 3) the coating needs to be able to withstand mechanical actions involved in mixing 
with feeds. The common ways to protect RPAA include calcium salts (e.g., Megamine-L™), 
lipids (e.g., Aji-Pro®-L, MetaboLys®, Bovi-Lysine™, AminoShure-M®), fiber/lipid 
combination (e.g., Mepron®), and lipid/polymer combination (e.g., Smartamine M®). 
One of the challenges with feeding RPAA is determining the availability of the AA to the 
animal (i.e., bioavailability). In vitro methods have been used, but they obviously lack effects of 
animal consumption and metabolism. In situ methods also have limitations, as the effects of 





rumen and absorption in the small intestine, products are subjected to hindgut fermentation, and 
any RPAA with small particle size or that are soluble cannot be tested. In vivo methods include 
ruminal and intestinal digestibility approaches, the milk protein dose-response, plasma area-
under-the-curve (AUC), and the plasma free AA dose-response. In the ruminal and intestinal 
digestibility approaches, like the in situ methods, the products are subjected to hindgut 
fermentation. For the milk protein dose-response, AA deficiencies in the diets must be 
maintained over the range of AA dosages used. For the AUC method, animals receive large oral 
or ruminal pulse doses of RPAA not otherwise encountered in typical farm feeding situations. 
The plasma free AA dose-response takes into account animal effects and variation as the product 
is fed under typical feeding regimes, but the methodology can be expensive and labor intensive. 
A standardized method to determine how much AA is available for the animal to use from 
RPAA needs to be proposed and accepted so that incorporation into ration formulation models is 
straightforward. 
 
Lysine and Methionine 
 Lysine (Lys) and methionine (Met) are either first limiting or co-limiting in most dairy 
cow rations formulated in the United States (Schwab et al., 1992a; Rulquin et al., 1993; NRC, 
2001). Lysine and Met are both essential amino acids (AA) for mammals and are used for 
protein synthesis e.g. growth, milk protein, tissue maintenance and repair, and gestation. They 
are also used for carnitine synthesis via an enzymatic pathway present in the liver and kidney, 
but not in skeletal or heart muscles (Champe et al., 2005). Carnitine is needed to transport fatty 
acids into cellular structures (Rebouche and Seim, 1998). Whereas Lys is also used to 





SAM in the process involved in DNA methylation,  formation of homocysteine, 
cystathionine/allocystathionine, cysteine, taurine, and glutathione, and indirectly involved in the 
formation of creatine, phosphatidylcholine (which can form VLDL and choline), and sarcosine. 
Both can also be metabolized and enter the Krebs cycle as a form of energy. 
 Lysine is a basic AA that is positively charged. It contains an amino group, carboxyl 
group, and a lysyl group (Figure 1). It is also hydrophilic, therefore it solubilizes easily in water 
and is this one of the reasons why it is hard to protect against ruminal degradation. It is a 
ketogenic AA that can be converted into acetyl-CoA, which enters the Krebs cycle. Yeast, fungi, 
and some green algae and some extreme thermophilic bacteria use the α-aminoadipic pathway to 
synthesize Lys, but as this is not the major synthetic pathway (Bender, 2012), and will not be 
further discussed. For plants and most bacteria, Lys is synthesized from aspartate using the 
diaminopimelate pathway (Nelson and Cox, 2008; Bender, 2012). In the diaminopimelate 
pathway, aspartate is converted to Lys through a series of steps as follows (Figure 2; Nelson and 
Cox, 2008; Bender, 2012): 
1. Aspartate is converted to aspartyl-β-phosphate by the enzyme aspartokinase using 
ATP as the energy source. 
2. Aspartyl-β-phosphate is converted to aspartate-β-semialdehyde by aspartate-β-
semialdehyde dehydrogenase using NADPH as a reducing agent. 
3. Dihydrodipicolinate synthase adds a pyruvate to aspartate-β-semialdehyde to form 
dihydropicolinate. 
4. Dihydropicolinate is converted to Δ1-piperidine-2,6-dicarboxylate by Δ1-piperidine-





5. Succinyl-CoA and water are added to the Δ1-piperidine-2,6-dicarboxylate by  N-
succinyl-2-amino-6-ketopimelate synthase to form N-succinyl-2-amino-6-keto-L-
pimelate. 
6. Succinyl diaminopimelate aminotransferase adds a glutamate to the N-succinyl-2-
amino-6-keto-L-pimelate to form N-succinyl-α,ε-diaminopimelate. This reaction also 
requires a pyridoxal phosphate. 
7. N-succinyl-α,ε-diaminopimelate along with water is converted to L,L- α,ε-
diaminopimelate by succinyl diaminopimelate desuccinylase. In this reaction a 
succinate is also formed. 
8. L,L- α,ε-diaminopimelateis converted to meso-α,ε-diaminopimelate by 
diaminopimelate epimerase. 
9. Meso-α,ε-diaminopimelate is converted to L-Lysine by diaminopimelate 
decarboxylase. This reaction also requires a pyridoxal phosphate. 
In Gram negative bacteria and plants, Lys can act as a negative feedback and inhibit  
aspartokinase, but this does not occur in Gram positive bacteria (Bender, 2012).  
 

















For Lys catabolism the saccharopine pathway (Figure 3) is the main pathway used by 
plants and most mammalian tissues, but the mammalian central nervous system uses the 
pipecolic acid pathway (Figure 4) (Bender, 2012).  In the saccharopine pathway, Lys is 






1. Lysine is converted to saccharopine by the enzyme saccharopine dehydrogenase. A α-
ketoglutarate is also needed and NADPH is the reducing agent. 
2. Saccharopine is converted to 2-aminodipic semialdehyde by saccharopine 
dehydrogenase. In this reaction  NADH is formed along with  glutamate. 
3. 2-aminodipic semialdehyde is converted to 2-aminoadipic acid by 2-aminodipic 
semialdehyde dehydrogenase. In this reaction  NADPH is formed. 
4. 2-aminoadipic acid is converted to 2-oxoadipoc acid by a transaminase. In this 
reaction another glutamate is formed. 
5. 2-oxoadipic acid is converted to glutamyl-CoA by 2-oxoadipic dehydrogenase. This 
reaction requires coenzyme and NADPH is formed. 
6. Glutamyl-CoA is converted to crotonyl CoA by glutamyl-CoA dehydrogenase and 
FADPH is formed. 
7. Hydroxyobutyryl CoA is formed when water is added to crotonyl CoA. 
8. Hydroxyobutyryl CoA is converted to acetoacyetyl CoA by hydroxyobutyryl CoA 
dehydrogenase and NADPH is formed. 
9. Acetoacyetyl CoA and coenzyme A combine to form acetyl -CoA 



























In the pipecolic acid pathway both L- and D-Lys is converted to acetyl-CoA through a 
series of steps as follows (Figure 4; Baumgartner and Verhoeven, 2003; Nelson and Cox, 2008; 
Bender, 2012): 
1. Lysine is converted to 2-oxo-6-aminocaproic acid by the enzyme Lys α-oxidase. In 
this reaction, a NH4
+





2. 2-oxo-6-aminocaproic acid is converted to Δ1-piperideinie-2-carboxylic acid by a 
non-enzymatic reaction. 
3. Δ1-piperideinie-2-carboxylic acid is converted to pipecolic acid by piperideine-2-
carboxylase reductase and NADPH is formed. 
4. Pipecolic acid is converted to Δ1-piperideinie-6-carboxylic acid by pipecolate 
oxidase. 
5. Δ1-piperideinie-6-carboxylic acid is converted to 2-aminodipic semialdehyde by a 
non-enzymatic reaction. 
6. 2-aminodipic semialdehyde is converted to acetyl CoA using steps 2 through 9 of the 
saccharopine pathway. 









Methionine is a non-polar aliphatic AA. It contains an amino group, carboxyl group, and 
S-methyl thioester group (Figure 5). It is hydrophobic; therefore, it does not dissolve easily in 
water. It is a glucogenic AA and is converted to succinyl-CoA, which will enter the Krebs cycle. 
For plants, bacteria, yeast, and fungi the sulfur to form Met comes from inorganic sulfur found in 
the environment (i.e., soil; Bender, 2012). Plants and microorganisms can synthesize Met from 
aspartate using the trans-sulfuration pathway (Figure 6). 
 
Figure 5. Chemical structure of Met. 
 
 
In the trans-sulfuration pathway, aspartate is converted to Met through a series of steps 
where homoserine is a precursor for Met synthesis as follows (Figure 6; Nelson and Cox, 2008; 
Bender, 2012): 
1. Aspartate is converted to aspartyl-β-phosphate by the enzyme aspartokinase using 
ATP as the energy source. 
2. Aspartyl-β-phosphate is converted to aspartate-β-semialdehyde by aspartate-β-
semialdehyde dehydrogenase using NADPH as a reducing agent. 
3. Aspartate-β-semialdehyde is converted to homoserine by homoserine dehydrogenase 





4. Homosereine is converted to O-succinylhomoserine by homoserine acyltransferase. 
In this reaction succinyl CoA is also needed. 
5. O-succinylhomoserine along with cysteine is converted to cystathionine using the 
enzyme cysthathionine γ-synthase. This reaction also requires a pyridoxal phosphate. 
6. Cystathionine is converted to homocysteine using the enzyme cystathionine β-lyase. 
This reaction also requires a pyridoxal phosphate and pyruvate is also formed. 
7. Homocysteine is converted to Met using the enzyme Met synthase, if the methyl 
donor 5-methyltetrahydrofolate is present. If it is not present, the homocysteine forms 
cysteine. 



















In bacteria, yeast, and fungi, the homoserine is formed from aspartate-β-semialdehyde. In 
plants, it is formed from homoserine O-phospahte, which is an intermediate precursor for 
threonine synthesis that forms homoserine (Bender, 2012). 
 In the trans-sulfuration pathway Met is converted to succinyl CoA or pyruvate through a 
series of steps as follows (Figure 7; Nelson and Cox, 2008; Bender, 2012): 
1. Methionine is converted to S-adenosylmethionine (SAM) by Met adenosyltransferase 
using ATP as the energy source. 
2. S-adenosylmethionine is converted to S-adenosylhomocysteine using a methyl 
transferase. In this reaction a methyl group is transfered to an acceptor and a 
methylated product is formed. 
3. S-adenosylhomocysteine is converted to homocysteine using water and 
adenosylhomocysteine nucleosidase and ribosylhomocysteine lyase. In this reaction, 
an adenosine and ribose are formed. The homocysteine has 2 paths it can take, it can 
be converted to Met using the enzyme Met synthase or it can be converted to 
cystathionine using cystathionine β-synthase, serine, and pyridoxal phosphate. 
4. Cystathoinine is converted to cysteine and 2-oxobutyrate using the enzyme γ-
cysthationase and pyridoxal phosphate. In the reaction a NH4
+
 is formed. 
5. Cysteine is converted to cysteine sulfonate which is then converted to sulfinyl 
pyruvate which is converted to pyruvate. 
6. 2-oxobutyrate is converted to propionyl CoA using α-keto acids dehydrogenase, 
Coenzyme A. In this reaction NADPH is formed. 
7. Propionyl CoA is converted to β-methylmalonly CoA using the enzyme propionyl 





8. β-methylmalonly CoA is converted to L-methylmalonly CoA which is then converted 
to succinly CoA using the enzyme -methylmalonly CoA mutase and a Coenzyme B12. 














Both Lys and Met are synthesized from aspartate by plants and microorganisms to 
aspartate-β-semialdehyde, but for Lys the aspartate-β-semialdehyde is converted to 
dihydropicolinate, and for Met is is converted to homoserine. Lysine and Met both undergo 
catabolism, but Lys is a ketogenic AA and Met is a glucogenic AA, so where they enter the 






Rationale for Balancing Diets for Amino Acids  
  The goal for balancing rations for livestock is to optimize the nutrient use efficiency by 
the animals. Ruminant nutrition differs from that of non-ruminants as the contribution of ruminal 
microbes, particularly microbial protein and its inherent AA, must be accounted for when 
formulating rations. The right combinations of nutrients, especially carbohydrates and proteins, 
need to be fed not only to maximize microbial growth, but also to meet the ruminants’ needs for 
energy and AA. When formulating diets for ruminants there are 2 protein fractions to consider: 
rumen-degradable protein (RDP), which is the proportion of dietary protein fed to meet the 
needs of rumen microorganisms, and rumen-undegradable protein (RUP), which is the 
proportion of dietary protein fed to complete the animal’s needs from absorbable AA (NRC, 
2001). The RUP also needs to have an AA profile that complements that provided by microbial 
protein, which may be difficult to achieve as the AA profile of ruminal microorganisms is not 
consistent. Rodrίquez-Prado et al. (2004), using continuous culture systems, studied the effects 
that fiber content and particle size had on liquid and solid associated bacteria AA patterns. There 
were some changes in AA profiles due to fiber content, but the larger differences were due to 
whether the AA were from the liquid or solid fraction. Lee et al. (2015) reported changes in 
bacterial species when DL, 2-hydroxy-4(methylthio) butanic acid (HMB) was fed. This could 
also have an impact on the AA content of microbial protein reaching the small intestine. There is 
considerable information in the literature that describes the essential AA (EAA) content of 
ruminal bacteria and common feedstuffs (Table 1). Most of the common RUP feeds fed to dairy 
cows in the United States are low in either Lys or Met or both (Table 1). This makes it 
challenging to find complementary RUP sources that are cost effective or, in the case of animal-





Table 1. A comparison of the essential amino acid composition of body lean tissue, milk, and 
ruminal bacteria with that of some common feeds (Schwab et al., 2003). 
Item Arg His Ile Leu Lys Met Phe Thr Trp Val 
 ──────────── (% of CP) ─────────────── 
Lean tissue
 
6.6 2.5 2.8 6.7 6.4 2.0 3.5 3.9 0.6 4.0 
Milk
 
3.4 2.7 5.8 9.2 7.6 2.7 4.8 3.7 1.5 5.9 
Bacteria
 
5.1 2.0 5.7 8.1 7.9 2.6 5.1 5.8 - 6.2 
           
Alfalfa silage
 
3.9 1.7 3.9 6.4 4.4 1.4 4.2 3.8 0.9 5.0 
Corn silage
 
2.0 1.8 3.3 8.6 2.5 1.5 3.8 3.2 0.4 4.5 
Grass silage
 
3.1 1.7 3.6 6.1 3.3 1.2 4.4 3.3 1.1 4.9 
           
Barley
 
5.1 2.3 3.5 7.0 3.6 1.7 5.1 3.4 1.2 4.9 
Corn
 
4.6 3.1 3.3 11.2 2.8 2.1 4.6 3.6 0.7 4.0 
Oats
 
6.8 2.4 3.8 7.3 4.2 2.9 5.2 3.5 1.2 5.2 
Wheat
 
4.7 2.4 3.3 6.6 2.8 1.6 4.6 2.9 1.2 4.2 
           
Brewers grains
 
5.8 2.0 3.9 7.9 4.1 1.7 4.6 3.6 1.0 4.8 
Canola meal
 
7.0 2.8 3.8 6.8 5.6 1.9 4.1 4.4 1.5 4.7 
Corn DDGS
 
4.1 2.5 3.7 9.6 2.2 1.8 4.9 3.4 0.9 4.7 
Corn gluten meal
 
3.2 2.1 4.1 16.8 1.7 2.4 6.4 3.4 0.5 4.6 
Cottonseed meal
 
11.1 2.8 3.1 5.9 4.1 1.6 5.3 3.2 1.2 4.2 
Soybean meal
 
7.3 2.8 4.6 7.8 6.3 1.4 5.3 4.0 1.3 4.6 
Sunflower meal
 
8.2 2.6 4.1 6.4 3.6 2.3 4.6 3.7 1.2 5.0 
           
Blood meal
 
4.4 6.4 1.3 12.8 9.0 1.2 6.9 4.3 1.6 8.7 
Feather meal
 
6.9 1.2 4.9 8.5 2.6 0.8 4.9 4.7 0.7 7.5 
Fish meal
 
5.8 2.8 4.1 7.2 7.7 2.8 4.0 4.2 1.1 4.8 
Meat meal
 
7.1 2.1 3.0 6.3 5.4 1.4 3.6 3.4 0.7 4.4 
 
Feeding rumen-protected AA (RPAA) such as RP-Met, RP-Lys or other AA like 
histidine can help to meet the animal’s AA requirements without overfeeding RDP and RUP, 
which can be beneficial to both animal and environment. To achieve the desired levels of 
metabolizable Lys and Met, high amounts of dietary protein are usually fed if RPAA are not 
included in the rations (NRC, 2001. Overfeeding of protein in dairy cow diets results in 
excessive N excretion, mainly as urinary N, which is considered to be the most environmentally 






Hristov et al (2011) reported that approximately ½ or more of the N excreted by cows is 
in the form of urea, which is rapidly hydrolyzed to NH3, and that this reaction is pH and 
temperature dependent. In the same study it was also reported that NH3 emission contributes to 
atmospheric fine particulate matter (ammonium sulfate, ammonium bisulfate, and ammonium 
nitrate) which contributes to air pollution. The authors estimated that NH3 emitted from livestock 
operations (feedlots and dairy farms) may contribute up to 20% of the atmospheric fine 
particulate matter in certain areas of the United States. So can feeding RPAA help to decrease 
the amount of urinary urea excreted, thereby decreasing the amount of NH3 that contributes to 
atmospheric fine particulate matter?  
 Lee et al. (2012) stated that one strategy to reduce N excretion, especially urinary urea 
excretion, is to reduce dietary protein, but that lowering protein may result in lower milk and 
milk protein yields. The authors fed diets that were adequate and deficient in protein and added 
RP-Lys and RP-Met to the diets to meet the recommended metabolizable protein Lys and Met. 
There was no effect on milk yield, but there was a significant decrease in milk protein content 
and yield with the deficient diets even though RP-Lys and RP-Met were added. The authors also 
reported a significant decrease in urine N, in urinary urea-N and a total N excreted with the lower 
protein diets that had RP-Lys and RP-Met added. The authors stated that the decrease in total N 
excreted resulted in a 40% decrease in the ammonia-emitting potential. Lee et al (2015) 
conducted a follow up trial where adequate protein diet and deficient protein diets that had RP-
Lys and RP-Met added were fed. In this trial they reported no decrease in milk yield or milk 
protein content or yield when the deficient diets with RP-Lys and RP-Met were compared to the 
adequate diet. Like in their previous trial there was a significant decrease in urine N, in urinary 





Chen et al. (2011) fed a high protein diet, a low protein diet that was supplemented with RP-Met, 
HMB and an isopropyl ester of HMB (HMBi), or HMB + RP-Met added. They observed no 
effect of treatments on milk yield, but there was a significant increase in milk protein content, 
with no effect on protein yield for the Met supplemented treatments. Similar to the Lee et al. 
(2012, 2015) trials there was a significant decrease in urine N and urinary urea N. Even though 
there are differing results with milk protein content and yield when low protein diets are 
supplemented with RPAA, all trials report decreased urinary N, in urinary urea-N, which could 
lead to decreases in atmospheric fine particulate matter. 
 Zanton et al. (2014) conducted a meta-analysis on 64 peer reviewed papers to evaluate 
the production responses of cows fed different supplemental dietary Met sources or 
postruminally infused with DL-Met. The diets fed varied in protein levels. Supplemental dietary 
Met sources were Mepron, Smartamine M, and HMB (provided either as a liquid or Ca salr 
form). Milk yields did not respond to Met supplementation, but there was an increase in milk 
protein yield for all sources of Met.  Milk protein concentration was greatest for all supplements 
or infusion, except for cows supplemented with HMB. Mepron and HMB also increased milk fat 
yield whereas milk fat concentration was only increased for infusion and for cows supplemented 
with HBB. Where component (milk fat and protein) pricing is in effect feeding RPAA may be 
beneficial. 
 Researchers at the University of Illinois conducted a trial to determine the potential 
health benefits for transition cows feed RP-Met. Osorio et al. (2013) reported that when 
transition cows were fed RP-Met 21 d before calving there was an increase in blood neutrophil 
phagocytosis at 21 d after calving compared to control cows. Cows in the same experiment were 





response to RP-Met fed to transition cows. Cows fed RP-Met had increased plasma tocopherol 
and an increase in the plasma oxygen radical absorbance capacity (Osorio et al., 2014). The liver 
concentrations of glutathione, retinal, and carnitine also increased in cows fed RP-Met. There 
was a decrease in bovine Il-6 along with ceruloplasmin and serum amyloid A, which may 
indicate a reduction in the pro-inflammatory signaling from the liver. The authors also reported 
that data indicated an increased assembly or export of very low density lipoproteins due to lower 
hepatic phosphatidylcholine concentrations with feeding RP-Met. Zhou et al. (2016) also 
observed a decrease in albumin and IL-6 levels in transition cows fed RP-Met, along with an 
increase in the concentration of total and oxidized glutathione levels in the liver. In these 3 
studies (Osorio et al., 2013, 2014; Zhou et al., 2016), the authors concluded that feeding RP-Met 
to transition cows 21 d before calving resulted in beneficial effects on the immune system. 
 Feeding RPAA can be a strategy to reduce the amount of N excreted to the environment, 
which could decrease atmospheric fine particulate matter. Overall, even though studies have 
reported differences in milk protein content and yields when low protein diets with RP-Lys and 
Met are fed, when Mepron, Smartamine M and HMB are fed there is an increase in milk protein 
yields for early lactation cows.  There may also be health benefits to AA balancing by feeding 
RPAA, at least in the transition cow. 
 
Rumen Protected Amino Acids 
Criteria for a rumen stable delivery system described by Wu and Papas (1997) are: 1) the 
system should provide rumen protection and post-ruminal bioavailability for the active 
ingredient, in the case of a RPAA it is the actual AA, 2) the components used in the rumen stable 





for the producer. Rumen protection initially focused on the use of heat or chemical treatments on 
proteins so that their degradation in the rumen was decreased and more of the protein would pass 
to the small intestine for digestion and AA absorption. An example of this is with soybeans 
where it has either been heated or treated with lignosulfonate (NRC, 2001). Using these 
approaches to deliver more AA to the small intestine is effective, but to deliver specific AA such 
as Met or Lys to the small intestine requires rumially protected forms of the individual AA 
Initially AA derivatives and analogues were studied, but due to high ruminal degradation 
or limited post-ruminal bioavailability they were considered poor sources of RPAA (Wu and 
Papas, 1997). Since then alternative methods of protection have been developed, such as 
embedding in calcium salts of long cahin fatty acids (Ca-salt) (e.g., Megamine-L™), lipid 
encapsulation (e.g., Aji-Pro®-L, MetaboLys®, Bovi-Lysine™, AminoShure-M®), fiber/lipid 
encapsulation (e.g., Mepron®), and lipid/polymer encapsulation (e.g., Smartamine M®). Chiang 
et al. (2009) proposed using chitosan encapsulation to protect AA. 
Wu and Papas (1997) described some desirable characteristics that a rumen-stable system 
should possess for both the coating (protective material) and core. Criteria that RPAA should 
possess are that they should be non-mutagenic, produce no adverse effects with long term use, 
and be able to pass through the rumen and deliver the AA to the small intestine. The core should 
have: 1) a high AA concentration, 2) optimal size, shape, and surface area for the coating to be 
applied, 3) optimal specific gravity, 4) sufficient hardness, so it does not fall apart in processing, 
and 5) once released from its protective coating it dissolves readily in the abomasum and/or 
gastrointestinal secretions so that it can be absorbed. The coating should: 1) have ruminal 
stability and be stable against the effects of mastication, rumination, and ruminal 





absorbed in the gastrointestinal tract, this is true for the polymer components, but the lipids and 
Ca-salts are absorbable, 4) have sufficient structural strength to handle most feed mixing 
practices, and 5) remain intact in feeds and TMR. Ji et al. (2016) conducted a study to determine 
what effects mechanical mixing and storage in TMR had on release of Lys from 6 different RP-
Lys supplements. Their results showed that for the products studied both mechanical mixing and 
extended exposure to TMR may damage the protective coating of RP-Lys products, thus 
potentially reducing the amount of Lys delivered to the small intestine.  
 Mepron (Evonick Industries AG, Hanaun, Germany) is a fiber/lipid combination RPAA. 
Mepron consists of a core of 85% Met and starch that has been coated with layers of 
ethylcellulose and stearic acid. Evonik states that Mepron
®
 is designed to release only 15 to 20% 
of the coated Met in the rumen and that over 90% of the remainding Met is absorbed along the 
small intestine. They state that these values were determined using the in situ method 
(www.evonik.com).  
 Smartamine M (Adisseo USA Inc., Alpharetta, GA) is a lipid/polymer combination 
RPAA. Smartamine M consists of a core of 75% DL-Met plus ethylcellulose covered with a coat 
of stearic acid containing small amounts of a pH sensitive polymer known as poly-2-
vinylpyridine-co-styrene. Presence of the copolymer is what helps with the rapid release of the 
product in the abomasum. Adisseo claims 80% bioavailability for Smartamine M based on the 
studies of Robert et al. (1997) and Rulquin and Kowalczyk (2003). This value was determined 
using the plasma AUC and the plasma free AA dose response methods. 
There are several RPAA with lipid protection. AjiPro-L (Ajinomoto North America Inc., 
Fort Lee, NJ) consists of an inner matrix core of 59% Lys hydrochloride (Lys-HCl), lecithin, and 





claims 40% bioavailability (Robinson et al., 2011). The methods used to determine the 
bioavailability of AjiPro-L was the highly protected L-Arg technique and a plasma free AA dose 
response method. In Bovi-Lysine (QualiTech Inc., Chaska, MN) the matrix and coating system 
consists of a combination of vegetable-based lipids and calcium salts of fatty acids that surrounds 
a core of 59% Lys-HCl. Qualitech claims 27% bioavailability, which was determined using a 
plasma free AA dose response method. AminoShure-M (Balchem Corporation, New Hampton, 
NY) consists of a Met core surrounded by hydrogenated vegetable oil. No bioavailability has 
been reported by Balchem (www.balchem.com). MetaboLys (H.J. Baker and Brothers Inc., 
Shelton, CT) is different from the other RP-Lys as it has a core of Lys sulfate, instead of Lys 
HCl, coated with hydrogenated soy oil. H. J. Baker claims 89% ruminal escape and 80% 
intestinal digestibility, which was determined using the in situ method (www.hjbaker.com). 
Megamine-L (Church and Dwight Corporation Inc., Princeton, NJ) is the main Ca-salt 
RPAA on the market. It consists of a core of 20% Lys-HCl with 80% Megalac™, which are 
calcium salts of long chain fatty acids from vegetable origins. Church and Dwight states that the 
high quality bypass of Lys and fat to the small intestine is achieved using EnergyShield (a patent 
pending process) that protects Lys from ruminal degradation. Church and Dwight claims 58% 
ruminal escape and 46% intestinal digestibility, which was determined using the in situ method 
(www.ahanimalnutrition.com).  
Methionine analogs have also been recognized as a source of Met that can be absorbed 
and converted to Met. The 3 major commercial Met analogs are Alimet (Novus International, 
Saint Charles, MO and Rhodimet AT88(Adisseo USA Inc., Alpharetta, GA), which are liquid 
sources of HMB and Metasmart (Adisseo USA Inc., Alpharetta, GA), which is HMBi that is also 





was to increase its resistance against microbial fermentation in the rumen so that more of the 
HMB would be absorbed and available for conversion to Met (Robert, 2004). 
Chitosan is a non-toxic polymer that is formed from the deacetylation of chitin. Chitosan 
has been shown to be biodegradable, and it has been used in various applications such as a 
carrier for enzymes, and has been shown to have antimicrobial activities (Matsuhashi and Kume, 
1997; Shantha and Harding, 2002). Encapsulation of an AA with chitosan requires that the AA is 
first entrapped in hydrogenated fat and then coated with the chitosan (Chiang et al., 2009). 
Chiang et al. (2009) used an in vitro test to determine how effect chitosan was on a protected Arg 
and Met product. When the products were incubated in a pH 5.5 phosphate buffer to simulate 
ruminal conditions, there was AA release, but the authors stated it was in acceptable limits. The 
products were then exposed to a pH of 1.0 to simulate abomasal conditions and the AA was 
released into the buffer. A second trial was conducted comparing their RP-Met product to 
Mepron using pH 5.5 phosphate buffer. The results were that after the pH 5.5 phosphate buffer 
86% of the Met remained in the products for both the chitosan based product and Mepron. The 
authors concluded that chitosan coating may be an effective way to deliver AA to ruminants, but 
that further research is needed. 
There are many RPAA supplements and Met analogs on the market that have a variety of 
protection methods, such as lipid/fiber encapsulation, lipid/polymer encapsulation, lipid 
encapsulation, and embedding in Ca-salts. Most of the commercially available products have 
claimed determined rumen bypass, intestinal degradation, and bioavailability values, but they 
were obtained using different methods, so it is hard to compare products against each other in 
terms of AA bioavailability to determine which one to use. The use of chitosan is a new 






Methods to Determine Metabolizable Amino Acid Supply from Rumen Protected Amino 
Acids 
In Vitro Methods 
 In vitro methods are laboratory based approaches intended to simulate ruminal 
escape and intestinal digestion. Some of the methods use ruminal fluid collected from sheep or 
cows, while others use buffers to mimic the ruminal environment (Mbanzamihigo et al. 1997; 
Ross et al., 2013; Miyazawa et al., 2014; Larson et al., 2015). Mbanzamihigo et al. (1997) 
evaluated the degradation rate of Met in the rumen and the effectiveness of Smartamine M and 
Mepron protection. Five treatments with the same N-equivalent, were subjected to different 
incubation times and total NH3-N production was determined by subtracting the NH3-H that was 
produced from incubation when starch was the only treatment. Ruminal fluid was collected from 
a sheep consuming a 50:50 hay:concentrate ration, diluted with Burroughs solution (Burroughs 
et al., 1950) under CO2, and the treatments were added to glass flasks. All treatments had starch 
added, so that energy was not a limiting factor. The flasks were incubated in a 39ºC shaking 
water bath for 2, 4, 6, 8, and 24 h and the NH3-N concentration was determined. Results are 
shown in Figure 8.   
The soya isolate (S) and the casein hydrolysate (C) were degraded faster than unprotected 
DL-Met (M), Smartamine M (Sm), and Mepron (Mp), with Smartamine M having the lowest 
NH3-N production. When the entire 24 h incubation period was considered, the total NH3-N 
production for Mepron and unprotected DL-Met were similar. The authors indicated that NH3-N 
production provided a good estimate of Met degradation, but stated that a disadvantage to this 





the released NH3-N may become incorporated into microbial protein and that this needs to be 
corrected for.  
Figure 8. Total NH3-N production for the 5 different substrates. 
 
 
 The in vitro method developed by Ross et al. (2013) to estimate intestinal digestibility of 
RUP in feeds was modified to be used to determine the efficacy of protection of RPAA. The 
modifications are the incubation times for both the ruminal and intestinal digestion phases and 
the enzymes used (Ross, personal communication). Figure 9 is a flow diagram outlining the steps 
used. 
In this method sample, the is weighed into an Erlenmeyer flask and both Van Soest buffer 
(Van Soest et al., 1991) and ruminal fluid are added under anaerobic conditions. Samples are 
then fermented for 4, 8, 12, 16, 24, and 30h at 39ºC (Ross, personal communication). At the end 
of each fermentation time point, contents of half of the flasks are filtered onto tared filter paper 





is left on the filter paper ought to represent what would escape the rumen. The other flasks are 
placed into a 39ºC shaking water bath and HCl is added to reduce the pH to below 2. The flasks 
are shaken for 1 min and pepsin is added followed by 1 h incubation. This step simulates what 
would occur in the abomasum. At the end of the 1-h incubation, NaOH is added to neutralize the 
pH and then trypsin, chymotrypsin, amylase, lipase, and bile salts are addedand mixed in a 
potassium phosphate buffer (Ross, personal communication). This step simulates what would 
happen when pancreatic secretions and bile salts mix with abomasal digesta. The flasks are then 
incubated for 16 h in a 39ºC shaking water bath (Ross, personal communication). At the end of 
the fermentation, samples are filtered on to tared filter paper for total N and AA analyses. This 
part of the procedure simulates intestinal digestion, because what is left on the filter paper ought 
to represent what would not be digested and would pass out of the small  intestine and be 
excreted in the feces. In this method, ruminal protection rate is determined by how much of the 
AA is left on the filter paper at the end of various times ruminal incubation and intestinal release 
is determined by how much AA is left on the filter paper after the 16 h exposure to pancreatic 
and intestinal enzymes. Thus, the more AA left on the filter paper after the ruminal incubation, 
the better the protection system. However, more AA left on the filter paper after the intestinal 
digestion phase would indicate over protection of the RPAA. 
Two other methods use the modified 3-step procedure of Gargallo et al. (2006) with some 
additional changes. The method of Miyazawa et al. (2014) replaced ruminal fluid with modified 
McDougal’s buffer that contains a lipase. To simulate the abomasal phase, an HCl buffer with 
pepsin was added and for the duodenal phase a phosphate buffer with pancreatin and gall powder 
was used. Rumen-protected Lys supplements (RP-Lys) were weighed into nylon bags and the 





Figure 9. The modified in vitro method of Ross et al. (2013). 
  
 
incubated for 20 h in the ruminal phase with aliquots of the solution in the flask being removed 
for AA analysis. The bags were then transferred to another vessel for the abomasal phase where 
the bags were incubated for 2 h. At the end of the 2 h period, an aliquot of the solution was 
removed for AA analysis and the bags were transferred to a third vessel for an 8 h duodenal 
phase incubation. At the end of the 8 h incubation, an aliquot of the solution was removed for 
AA analysis (Figure 10).  The results obtained from Miyazawa et al. (2014) are shown in Figure 
11. Most of the product differences were associated with differences in rates and extent of 
ruminal release rather than in rates of intestinal release. 
The amount of Lys that escaped was calculated as [amount of Lys in the RPAA – the 
amount of AA in each buffer]. This value is the amount of Lys that would not end up in the 





an in situ method and stated that the correlation between the 2 methods was greater than 0.90. 
The authors also stated that future research needs to be done with different ruminal pH 
conditions, because when the pH was reduced one of the products tested had a higher ruminal 
protection value. 




 Larson et al. (2015) modified the Miyazawa et al. (2014) method to use media bottles, 
instead of the dissolution apparatus, to make the method more economical. Otherwise the 
method was the same, with a 20 h incubation for the ruminal phase, 2 h for the abomasal phase, 
and 8 h for the duodenal phase. One of the objectives of the study was to look at consistency of 
results when using this method. Three RP-Lys were subjected to 3 replications and within each 
replication there were 3 runs. The parameters examined were ruminal insoluble Lys, abomasal 
insoluble Lys, and intestinal available Ly. All data were analyzed using a one-way ANOVA. The 
authors stated that when the runs were combined together for each replicate there was no 
variation observed amount replicate, but there was variation between runs in a replicate for the 
ruminal insoluble Lys and abomasal insoluble Lys, but not for intestinal available Lys. The 
authors concluded that this method can be used to determine product differences in Lys 





rates were determined by how much Lys were present in the fluid aliquots collected at the end of 
the ruminal, abomasal, and intestinal phases. Thus, if there were little to no AA in the ruminal 
aliquot then the RP-Lys had a high ruminal protection and so forth.  
 All the in vitro methods to test RPAA protection and intestinal availability of AA have 
one major shortcoming, which is the lack of animal effects or variation. They are also factorial 
approaches that use independent value determined for ruminal escape and another value for 
intestinal absorption. They also assume that AA present in the intestinal phase are absorbed and 
used by the cow. For products like Mepron, which depends on the abrasive action of feeds in the 
rumen to start to disrupt their protective layers, this does not occur and therefore, an overestimate 
of rumen protection can be reported. Miyazawa et al. (2014) also reported different amounts of 
Lys released by RP-Lys supplements with different incubation times in the rumen phase (Figure 
11). 
 
Figure 11. In vitro measurement of RP-Lys supplements using a modified 3-step method 







If an in vitro method could be standardized so that incubation times, pH of incubation 
solutions, and the enzymes used and their concentrations are the same across laboratories, this 
methodology could be more useful in preliminary evaluations of RPAA supplements. The 
method could also be used for checking the quality of the RPAA supplements from lot to lot or 
year to year. The in vitro method is less costly, quicker to run, and more samples can be analyzed 
compared to in situ and in vivo methods. 
In Situ Methods 
In situ methods are animal based factorial approaches that get measurements for both the 
ruminal escape and intestinal disappearance. The in situ method used to determine bioavailability 
of RPAA supplements generally relies on using bags for a ruminal incubation for obtaining 
estimates of rumen escape and the mobile bag method for obtaining estimates of intestinal 
disappearance. 
The in situ bag method (Overton et al., 1996; Berthiaume et al., 2000; Koenig and Rode, 
2001) consists of weighing the RPAA into dacron or nylon bags, which are then incubated in the 
rumen of ruminally fistulated cows.  The incubation times can be fixed, usually 16 h, or variable 
depending if the objective of the trial is to determine ruminal release over time. The bags are 
removed from the rumen and washed under cold tap water until the water runs clear. The bags 
are then transferred to a container containing an HCl-pepsin solution at 39ºC incubation for 1 to 
2.5 h, which is done to simulate the conditions of the abomasum. After incubation bags can be 
rinsed with distilled water and dried either with a freeze dryer or forced air oven. Material from 
the bags is then placed into smaller bags and inserted into the duodenum via a duodenal cannula, 
usually at 15 min intervals until all the bags have been inserted. The bags are recovered from the 





oven at 55ºC for 48h or freeze dried. Bags can also be collected from the ileum. Berthiaume et al. 
(2000) used ileal cannulated heifers to collect bags to determine how much Met disappeared in 
the small intestine from a RP-Met supplement. 
 Bioavailability is calculated as: 
% of AA that escapes the rumen × % of AA that disappears in the intestine 
An example is the Berthiaume et al. (2000) trial where a RP-Met was incubated in the 
rumen for 4.5 h.  It was determined that with the rumen escape of the RP-Met was 83.9% and the 
intestinal disappearance was 56.8%, yielding an average bioavailability value of 47.7% [(0.839 × 
0.568) × 100]. 
 There are inherent limitations and errors resulting in over- or underestimation of 
bioavailability values of RPAA supplements using the in situ method. The first limitation is that 
the effects of eating and rumination are not considered. Placing the bags into the rumen protect 
the products from these 2 processes. Secondly, flow out of the rumen for the RPAA is important 
because this can lead to over- or underestimation of how much product is actually escaping the 
rumen. This can be seen with the results for the Overton et al. (1996), Berthiaume et al. (2000), 
and Koenig and Rode (2001) where bags containing Mepron were incubated in the rumen for 
different time points. As incubation time increased ruminal disappearance form the bags 
increased with times above 12 h, had more AA was released from the RPAA than what was 
shown at the 3 and 6 h incubation times. Therefore, the greater the retention of the RPAA in the 
rumen,that smaller the amount of the RPAA that makes it to the small intestine. Depending on 
the ruminal retention time selected, this will impact the calculated bioavailability values. Third, 
the in situ method cannot be used for fine or soluble RPAA since they would escape the bags 





Inherent errors with the in situ method includes the assumption that disappearance from 
the bags in the rumen means degradation and that disappearance from the mobile bags collected 
in the ileum or in the feces means absorption. These assumption may or may not be true. The 
other errors occur because the method has not been standardized for RPAA supplements. Bag 
size and sample size can have an effect on disappearance from the bags. Vanzant et al. (1998) 
summarized the literature and stated that for conventional feedstuffs, as the ratio of sample size 
to bag surface area increased, disappearance from the bags. Berthiaume et al. (2000) also stated 
that this may be a one of the reasons for why there are differences in rumen stability among 
studies using the same RPAA supplement. Pore size can also affect disappearance from the bags, 
with larger pore sizes usually resulting in more disappearance from bags (Weakly et al., 1983; 
Nocek, 1985). Vanzant et al. (1998) also stated that for bags flowing through the small intestine 
the pore size may limit the opportunities for mixing and compression and that the impact of this 
effect may be more important than the impact during the rumen phase. Berthiaume et al. (2000) 
noted that the physical barrier created by the bags may contribute to lower disappearance in the 
small intestine because it restricts the contact that the RPAA supplement has with the digesta. 
Vanzant et al. (1998) reported that any dietary factors that influence the ruminal microorganisms, 
such as starch and soluble protein concentrations and degradation of dietary proteins, have the 
potential to affect the rate and/or extent of degradation in the bag. Overton et al. (1998) found 
that the dietary sources of carbohydrate and protein may effect on what contribution the large 
intestine has on Met digestion of RPAA supplements. When RPAA are subjected to hindgut 
fermentation, the observed disappearance of the AA in the intestinal tract could have occurred in 
the small and large intestine, but it is assumed to have taken place in the small intestine only, 





Berthiaume et al. (2000) stated that their data agreed with other research that for Mepron 
entering the large intestine there is a high potential for it to be digested. How samples are 
handled after the rumen phase can also be a problem. Overton et al. (1996), Berthiaume et al. 
(2000), and Koenig and Rode (2001) washed the bags from the rumen with cold tap water until 
the water ran clear, whereas Wu et al. (2012) and Evans et al. (2015) washed in cold tap water 
but then placed them in a washing machine to remove feed and microbial contamination. The 
effect that agitation in a washing machine has on the integrity of the coating of the RPAA has not 
been studied. This could lead to fractures in the coating resulting in more AA being removed in 
the washing machine, thus resulting in lower ruminal escape values, or the potential fractures 
could result in more AA being released in the intestine leading to higher intestinal digestibility 
values and therefore, under- or overestimated bioavailability values. Another point of concern is 
how the samples are handled after they are washed. Overton et al. (1996), Berthiaume et al. 
(2000), and Koenig and Rode (2001) placed the washed bags into the pepsin-HCl solution and 
then proceeded to the duodenal cannula. Wu et al. (2012) dried their samples in a forced-air oven 
and took subsamples that were placed into bags for the pepsin-HCl solution, and after a 2 h 
incubation they were stored at -18ºC until introduced into the duodenum. What effects the 
forced-air oven and freezing had on the coating was not studied, but both processes may have 
compromised the coating leading to over- or underestimations of bioavailability.  
The in situ methods, like the in vitro methods, can be used to conduct preliminary 
evaluations of RPAA.  
In Vivo Methods 
In vivo methods have the advantage of providing animal-derived estimates of efficacy 





include the highly protected L-Arg method, a method described by Watanabe et al. (2003) as 
explained in detail below, the milk protein dose response method (Schwab et al, 2001; Ordway et 
al., 2013), the plasma AA area-under-the–curve (Robert et al., 1997; Graulet at al., 2005; 
Devillard et al., 2011; Faivre et al., 2013; Evans et al., 2013), and the plasma free AA dose 
response method (Rulquin and Kowalczyk, 2003; Borucki Castro et al., 2008; Hanigan et al., 
2009). 
The highly protected L-Arg method was first used by Swanepoel et al. (2010) and then by 
Robinson et al. (2011) and Miura et al. (2016). This method uses a highly protected, 
undegradable L-Arg product (HP-Arg) that has the same specific gravity and particle size as the 
RPAA to be tested, resulting in both the indigestible marker, HP-Arg, and the test supplement 
having the same rumen escape kinetics. The HP-Arg and RPAA are fed to cows with duodenal 
cannulas and duodenal fluid was collected at 3 h intervals for 48 h. The HP-Arg and RPAA 
particles are removed from the digesta, and the particles are crushed so that the Arg and test AA 
are released to determine their concentrations. The Arg and AA concentrations are plotted and an 
AUC calculation was done. The ruminal escape rate was calculated as the ratio of AA to Arg, 
with the Arg having an assumed escape rate of 100% (Figure 12). 
The second step was to collect fecal samples to determine basal concentrations of the test 
AA before cows are fed the test RPAA. Cows are then fed the RPAA and feces are collected at 
12 h intervals for 72 h, so that there are 6 subsamples. These samples are homogenized with hot 
water (60-70ºC) to extract free AA in the feces. Fecal free AA theoretically originated from the 
indigestible portion of the RPAA. The basal levels of AA are then subtracted from the free AA in 
the RPAA fed cows and called fecal excreted AA. Post-ruminal released AA was calculated as:  





Bioavailability was calculated as:  
% ruminal escape rate × % post-ruminal released AA 
Robinson et al. (2011) used the method to evaluate a RP-Lys that contained 40.4 % Lys. 
Seventy-two percent of the RP-Lys was calculated to have escaped ruminal degradation and  
14.4 g was calculated to have been excreted in the feces. Therefore 29.1 g of Lys escaped 
ruminal degradation (0.72 × 40.4) and the post-ruminal release was 0.505 [1-(14.4/29.1)]. The 
estimated bioavailability was 36.4% (72 × 0.505). 
Figure 12.   Lys and Arg area-under-the-curve results using the highly protected L-Arg method 









Watanabe et al. (2003) used a digestibility technique to determine abomasal outflow and 
fecal collection to determine intestinal disappearance of a RPAA supplement. In their trial, 
Holstein heifers with T-shaped cannulas were used. A balloon catheter was inserted into the 
distal side of the cannula and inflated so that digesta from the abomasum was diverted to the 
stem of the cannula for collection. Digesta was sampled before the RPAA was feed to determine 





and divided into solid and liquid phases, which were analyzed for the free AA for the RPAA 
(Figure 13). Hourly recovery rates were determined by multiplying the AA in the abomasal 











Figure 13. Schematic of the sampling procedure for abomasal outflow (Watanabe et al., 2003). 
 After the abomasal outflow portion of the trial was completed, the same animals were 
submitted to total fecal collection for basal values of AA and were then fed a known amount of 
the RPAA. Amino acid analysis was done on the feces to determine intestinal disappearance. The 
recovery of Lys from abomasal outflow was 23.9% for the liquid phase and 34.3% for the solid 
phase giving a total of 58.3% for Lys, for Met, it was 68.6% for the liquid phase and 9.7% for 
the solid phase giving a total of 78.3%. The recovery rate from the feces was 8.8% for Lys and 
0.0% for Met. Intestinal disappearance was calculated to be 49.5% (58.3 - 8.8) for Lys and 





For both the highly protected L-Arg and the Watanabe et al. (2003) methods the RPAA is 
subjected to hindgut fermentation, so it must be assumed that some disappearance of the AA 
occurs in the large intestine, and that the methods assumes it to take place only in the small 
intestine, which can lead to at least some overestimation of bioavailability, similar to the in situ 
method. For the highly protected L-Arg method, developing a HP-Arg for every RPAA to make 
sure the specific gravity and particle size matches can be very costly. The method used by 
Watanabe et al. (2003) can have problems maintaining good flow rates from the abomasum for 
getting a representative sample and if the balloon fails then the samples obtained are not 
representative of a total collection. 
The milk protein dose response is an indirect method to determine bioavailability. The 
rationale for this method is that milk protein concentrations are sensitive to changes in 
metabolizable AA supply and that milk protein concentrations increases linearly until levels of 
adequacy are met and then plateau. Schwab et al. (2001) and Ordway et al. (2013) used this 
method to determine bioavailability for Met analog supplements. Schwab et al. (2001) used a 
replicated 5 × 5 Latin square design where 5 levels of Smartamine M were fed in one replicate, 5 
levels of HMBi were fed in another replicate and 5 levels of HMB were fed in the last replicate. 
The basal diet was formulated to be Met deficient and the levels fed went from deficient which 
was 0 g/d of supplemental Met to adequate which was 25 g/d for Smartamine M and 30 g/d for 
HMB and HMBi. Ordway et al. (2013) also used a replicated 5 × 5 Latin square design where 5 
levels of Smartamine M and HMBi were fed but in this study the diets in 2 of the replicates were 
formulated to be Met deficient and in the other 2 replicates the diets were formulated to be Met 
adequate. Cows were fed their respective treatments for 14 d with milk samples being collected 





the Met analogs to. Bioavailability was calculated using the dose response relationship for the 
linear portion of the line:  
      Response slope of changes in milk protein concentration of Met analog   
Response slope of changes in milk protein concentration of Smartamine M 
A limitation with this method is that a deficiency of the AA needs to be maintained in all 
cows, over most of the dosages used. Unfortunately, this cannot be determined beforehand. 
Another limitation is that the changes in milk protein are indirect measurements of increasing 
adequacy of the limiting AA. Since this is an indirect measurement the confidence intervals (CI) 
may be large and therefore the accuracy of the bioavailability value is decreased. Finally, the 
energy content of the diet t needs to be maintained at adequacy throughout the study. There are 
some advantages of the milk protein dose response method over the in vitro and in situ methods. 
First the method does not require the use of ruminally-cannulated cows. The higher the 
production cow, the more ideal the cow is for this method as it is easier to create an AA 
deficiency and response to increasing amounts of the RPAA. Second, the RPAA are incorporated 
into the diet and are subjected to the all of in vivo effects of consumption and rumination as well 
as the effects that the diet has on the RPAA. For the in vitro and in situ methods this is not a 
common practice. There are also no restrictions on the physical nature of the RPAA being 
evaluated as it can be a liquid or consist of small particles. Finally, it has been observed that 
changes in milk protein concentration to increased supplies of limiting AA are relatively fast 
allowing for the use of Switch-back or Latin Square designs (Rulquin et al, 1993; Schwab et al., 
1992a, 1992b).  
 The AUC method uses ruminally cannulated lactating or dry cows that have been fitted 
with jugular catheters for blood collection. Initial blood samples are taken before AA 





concentration of the test AA. The animals are then given the AA treatments as a pulse dose. For 
the positive control treatment, the test AA is given via abomasal infusion. The RPAA is usually 
provided as a bolus dose via the ruminal cannula. For the infusion, the entire dose of the AA is 
infused within the first 2 h of the blood collection period. Blood samples are then taken at set 
time points, usually every 1 to 2 h for the first 14 h and then less frequent until either 48 or 72 h 
after dosing to ensure that there is a return to baseline concentrations. All plasma samples are 
analyzed for the AA of interest. The baseline values for each cow are averaged together and 
subtracted from the values obtained after supplementation (Graulet et al., 2005). The resulting 
values are then graphed and elemental trapezoidal AUC analysis is done by multiplying the mean  
AA concentration increases between 2 consecutive sampling times and the duration of the 
interval. The total AUC is the sum of the calculated elemental AUC (Graulet et al., 2005). An 
example of an AUC is shown in Figure 14. 
Figure 14. Area-under-the-curve for a Lys test product (Schwab, 2009; unpublished data) 
 
 
 One of the major limitations with the AUC method is that the animals receive a large 





in normal feeding conditions. Another limitation is that the RPAA is not consumed by the animal 
or exposed to the TMR. The pulse dose is usually deposited directly through the rumen cannula 
into the rumen at the level of the liquid phase just under the fibrous material (Graulet et al., 
2005), likely resulting in it flowing out of the rumen faster than if it was fed. If the pulse dose is 
a RP-Met the effects it has on the other sulfur AA is not take into consideration. Finally, it has 
been observed that estimates of bioavailability are linearly related to the amount of the pulse 
dose, with higher doses yielding higher estimates of bioavailability (Graulet et al., 2005; Evans 
et al., 2013). This method is quicker and more convenient than milk protein dose response and 
because it is a direct measurement the precision for the bioavailability is better resulting in lower 
CI, but due to all the limitations it is not the best method to determine bioavailability. 
 The plasma free AA dose response method is a more direct method because it identifies 
changes in plasma AA concentrations as increasing amounts of an AA are supplied. One of the 
criteria for the plasma free AA dose response method is that a linear relationship exists between 
the graded amounts of fed or infused AA and the concentration of the AA in the plasma. This 
relationship has been demonstrated for both Lys and Met by several researchers (King et al., 
1991; Rulquin and Kowalczyk, 2003; Borucki Castro et al., 2008; Hanigan et al., 2009). This 
linearity has been demonstrated for both AA in ranges that go from known deficiencies to 
beyond adequacy.  
 Rulquin and Kowalczyk (2003) were the first researchers to use a plasma free AA dose 
response method to determine bioavailability of RPAA supplements. They first developed an 
animal response calibration with water as the control and then graded levels of an AA to develop 
a response curve for each animal. Then the RPAA is also fed in graded levels similar to the 





cannula, whereas the RPAA were placed into the rumen via the rumen cannula twice a day 15 
min after the 0630 and 1830 h feeding. Blood samples were taken via jugular catheters every 
hour for 12 h on the last day of the 4-d experimental period. Amino acid analysis was done on 
deproteinized plasma samples. The plasma concentrations of AA were statistically analyzed for 
linear and quadratic effects to ensure that responses were linear and then the slopes and 
intercepts were compared. The researchers concluded that the variability of the plasma free AA 
dose response method was 3-10% for Smartamine M, whereas Robert and Williams (1997) using 
the in situ method reported a 20-30% variability in estimates of bioavailability. A comparison of 
results from these two experiments indicates that the plasma free AA dose response method is a 
more percise method to determine bioavailability. Rulquin and Kowalczyk (2003) also stated 
that the animal response calibration should be performed on individual cows to ensure optimal 
precision. Hanigan et al. (2009) used the plasma free AA dose response method to determine the 
bioavailability of a RP-Lys supplement. In their study, 1 set of cows was abomasally infused 
vwith graded amount of Lys and used for the calibration portion of the study and a different set 
of cows was used for feeding the graded amounts of the RP-Lys. This lead to large animal 
variations as seen by the standard errors,  so it is important to use the same cows for all 
treatments as done by Rulquin and Kowalczyk (2003) and Borucki Castro et al. (2008). The diets 
fed to animals can be either AA adequate or deficient and responses are still observed. Rulquin 
and Kowalczyk (2003) used an AA deficient diet to develop the calibration and RPAA slopes, 
whereas Borucki Castro et al. (2008) used an AA adequate diet. Borucki Castro et al. (2008) 
used the plasma AA dose response method as a non-invasive technique to determine how 
different treatments of soybean meal had affected Lys availability. The assumption that the AA 





replicated in order to capture animal variation and improve the precision of the methodology. 
The strength of this method compared to the others, in addition to providing animal derived 
values, is that steady state conditions can be obtained. Rulquin and Kowalczyk (2003) observed 
that steady state conditions for appearance of the AA in the blood were reached after 4 d of 
treatment.  There may be significant diurnal variations for the AA, but overall mean 
concentrations do not appear to change after day 4 of providing treatments. 
 Many methods are currently being used to determine the bioavailability of AA in RPAA 
supplements. All the methods have limitations and strengths. The in vitro and in situ methods 
appear to be good methods to get initial assessments of the potential efficacy of RPAA 
supplements. It appears that the described in vivo methods, if conducted appropriately, methods 
should yield the more reliable estimates of AA bioavailability since they provide the most direct 








The plasma free amino acid dose-response technique: A proposed methodology for 
determining lysine bioavailability of rumen-protected lysine supplements 
Introduction 
Lysine, along with Met, are the 2 most limiting AA in dairy cow diets in North America 
(NRC, 2001). Increasing Lys in MP typically results in an increase in milk protein content and 
yields when it is the first limiting or a co-limiting AA (Schwab et al., 1992b). Several rumen-
protected Lys (RP-Lys) supplements have been produced and commercialized by the dairy 
industry with the general goal of optimizing the concentration of Lys in MP. Availability and 
variability in quality, digestibility, and cost of blood and fish meals have made RP-Lys 
supplements an attractive alternative, or a partial substitute, to these high RUP, high Lys 
containing protein sources. The RP-Lys supplements currently available on the market differ not 
only in terms of encapsulation technology, but also in size, density, and Lys concentration.  
Available research also indicates that the availability of Lys to ruminants (i.e., bioavailability) 
from these supplements varies widely, making reliable estimates of Lys bioavailability essential 
when considering the use of RP-Lys supplements. Even though most companies provide 
estimates of Lys bioavailability for their RP-Lys supplements, these values are not obtained 
using a standardized scientifically accepted technique or methodology. Therefore, it is 
challenging to accurately compare RP-Lys supplements in their ability to provide metabolizable 
Lys without standardized methodology.  
Current factorial approaches used to evaluate ruminally-protected AA (RP-AA) 
supplements include in vitro (Ross et al., 2013) and in situ (Overton et al., 1996; Berthiaume et 





obtain estimates of ruminal escape and intestinal absorption of Lys from RP-AA supplements 
from which estimates of bioavailability are calculated. The major limitation for the in vitro 
approach is the absence of all animal effects. While the in situ approach subjects feedstuffs to 
rumen fermentation and intestinal digestion, several limitations exist including (1) the absence of 
chewing and rumination effects, (2) potential discrepancy between disappearance from a bag and 
actual ruminal degradation of the supplements, and (3) low reliability when testing fine or 
soluble supplements because they may be washed out of a the bag (NRC, 2001; Robert, 2004). In 
vivo techniques that have been used to determine AA bioavailability include the plasma AA 
area-under-the-curve method (Graulet et al., 2005), the production response approach (Schwab et 
al., 2001), and the plasma AA-dose response technique (Rulquin and Kowalczyk, 2003; Borucki 
Castro et al., 2008). The limitation of the area-under-the-curve technique is that a single pulse 
dose of the RP-AA may deliver the total daily amount that a cow would normally consume 
throughout the day at 1 time point. The production response approach does not always result in a 
linear response between measured milk protein content or yield and graded doses of the RP-AA. 
In reported plasma-dose response technique studies, not all treatments (i.e., infused and fed doses 
of AA) were tested simultaneously within the same Latin square (Rulquin and Kowalczyk, 2003; 
Hanigan et al., 2009). 
The plasma free Lys dose-response technique that we are proposing herein is a 
refinement of the plasma AA-dose response developed by Rulquin and Kowalczyk (2003). The 
technique relies on a positive linear relationship between incremental amounts of infused or fed 
Lys and plasma Lys concentration. A linear relationship between incremental doses of infused 
Lys into the omasum, abomasum, or duodenum, and plasma Lys concentration has been reported 





we are proposing that all treatments (i.e., infusion of Lys and fed doses of RP-Lys) be 
simultaneously provided in the same Latin square to minimize variation. We hypothesize that 
increases in plasma Lys concentrations reflect increase net absorption of Lys and that as a result 
changes in plasma Lys can be used to calculate reliable estimates of the bioavailability of Lys 
from RP-Lys supplements. The objectives of this study were: (1) to confirm linearity of the 
response between infused incremental amounts of infused Lys and plasma Lys concentration, (2) 
to examine the variation that exists among cows in changes in plasma Lys concentrations to 
increasing amounts of absorbed Lys, and (3) to evaluate a RP-Lys supplement with a previously 
established estimate of expected bioavailability (Robinson et al., 2011).  
 
 
MATERIALS AND METHODS 
All procedures related to animal care were conducted with approval of the University of 
New Hampshire Institutional Animal Care and Use Committee (IACUC no. 070902, 091201, 
110502, 111103, 121201, and 130904). All experiments were conducted at the University of 
New Hampshire Fairchild Dairy Teaching and Research Center (Durham, NH). 
Experimental Design and Treatments 
The data for this paper are the infusion treatment data from 13 Latin square studies that 
were conducted at the University of New Hampshire to determine bioavailability of Lys in RP-
Lys supplements. In Study 1, Lys was infused into the duodenum using duodenally-cannulated 
cows. All cows were injected with sometribove zinc suspension (Posilac, Protiva, St. Louis, MO) 
on the first day of each 14-d experimental period. In Studies 2 to 13, Polilac was not 





ingredient composition of the basal diets and the nutrient composition of individual feedstuffs 
are presented in Tables 2 and 3, respectively. The experimental design and conditions are 
presented in Table 4. Duodenal infusions were conducted following the procedure of Schwab et 
al. (1992b) and abomasal infusions were conducted following the procedure of Gressley et al. 
(2006). The experimental treatments were incremental doses of Lys (Table 4). Smartamine M 
(Adisseo USA, Inc., Alpharetta, GA) was fed in all studies with the exception of Study 10 in 
which MetiPEARL (Kemin Industries Inc., Des Moines, IA). The RP-Met supplements were fed 
to help ensure that diets were Met adequate according to the NRC (2001). Since Lys and Met are 
generally recognized as the 2 most limiting AA in most dairy cow diets and the technique is 
designed to study the effects of supplemental RP-Lys on plasma AA profile, it was considered 
important to make sure that Met was adequate so Met deficiency has no adverse effects on the 
plasma total AA profile (NRC, 2001). The infusion treatments consisted of Lys-HCl (80% Lys; 
assumed Lys bioavailability of 100%) or Lys sulfate (50.7% Lys; assumed Lys bioavailability of 
100%). The infusion solutions were prepared daily (at 1350 h for Study 1, 1530 h for Study 2, 
and at 1400 h for Studies 3 through 13) by mixing the Lys-HCl or Lys sulfate with 4 L of warm 
tap water. Solutions were infused using peristaltic pumps (Manostat; Barnant Co., Barrington, 
IL; Masterflex; Cole-Parmer, Vernon Hills, IL). Pumps were turned off and the infusion lines 
disconnected during milking times for approximately 45 min per milking. Pumping rates (175 
mL/h) were adjusted and monitored to ensure uniform and complete daily administration of Lys. 
The RP-Lys supplements were mixed with 1.5 kg of TMR, placed in rubber tubs, and fed 30 min 
before each of the 3 daily feedings. Total mixed ration plus RP-Lys supplements not consumed 





Management of Cows 
Cows were housed in a naturally ventilated tie-stall barn, fed individually and ad libitum 
with minimal orts (2 to 4%), and had access to water throughout the duration of the experiments. 
Cows were milked 3 times daily at 0550, 1350, and 2150 h in Study 1 and twice daily at 0430 
and 1530 h in Studies 2 through 13. Milk weights recorded were during each milking. Cows 
were fed 3 times daily at 0600, 1400, and 2200 h in Study 1, and at 0500, 1400, and 2100 h in 
Studies 5 through 13, and twice daily at 0500 and 1500 h in Studies 2, 3, and 4. Samples of TMR 
and orts were collected daily and composited by equal weight in each period for determination of 
DM. The NRC (2001) evaluation of all basal diets is presented in Table 2. 
Samples of corn and haycrop silages were collected daily throughout the studies. Alfalfa 
hay was sampled by using a Hilti model TE 7-A drill fitted with a 40-cm long metal core sampler 
(Hilti North America, Tulsa, OK). Blood meal, fat, and mineral mixes were collected weekly. 
The individual feedstuffs used to make the concentrate mix were sampled at the feed mill (Poulin 
Grain, Newport, VT) and sent to the University of New Hampshire Fairchild Dairy Teaching and 
Research Center. Ingredients used in Studies 2 through 13 were freeze-dried (Labconco Model 5, 
Kansas City, MO) for 48 h, whereas ingredients used in Study 1 were dried to 88% DM for a 
minimum of 12 h in a forced hot air oven at 60°C (VWR Scientific, Radnor, PA). Samples were 
then stored in air-tight glass jars until the completion of each study and ground to pass through a 
1-mm screen using a Wiley mill (Thomas Scientific; Arthur H. Thomas, Philadelphia, PA) 
before chemical analysis.  
Composites of each ingredient were shipped to a commercial laboratory (Dairy One 
Cooperative Inc., Ithaca, NY) for nutritional analyses according to the following methods: DM 





method 6 (NDF in feeds-filter bag technique for A200; Ankom Technology, Fairport, NY); 
solutions as in Van Soest et al., 1991], ADF [Ankom Technology method 5 (ADF in feeds-filter 
bag technique for A200; Ankom Technology); solutions as in method 973.18; AOAC, 1998], 
crude fat (method 2003.05; AOAC, 2006), and ash (method 942.05; AOAC, 2006). Feeds were 
also analyzed for AA content (cation-exchange chromatography coupled with post-column 
ninhydrin derivatization and quantitation method; method 982.30; AOAC, 2006; University of 
Missouri Experimental Station Chemical Laboratories, Columbia, MO). 
Milk Sampling and Analysis  
Milk samples were collected at each milking during the last 3 d of each experimental 
period. No milk samples were taken for Studies 3 and 4. Samples were preserved in tubes 
containing 2-bromo-2-nitropropan-1,3 diol (Broad Spectrum Microtabs II; Advanced 
Instruments, Inc., Norwood, MA), pooled by cow for each day according to daily milk weights, 
and refrigerated at 4°C until shipped to a commercial laboratory for determination of fat, true 
protein, lactose, and MUN by mid-infrared reflectance spectroscopy (Dairy One Cooperative, 
Inc.). 
Blood Sampling and Analysis   
Blood samples were collected 3 h after the morning feeding on d 10 for study 1; 3 h after 
the morning feeding on d 19 and 21 for study 2; 1.5, 3.0, 4.5, and 6.4 h after the morning feeding 
on d 4 for studies 3 and 4; and 2, 4, 6, and 8 h after the morning feeding on d 5, 6, and 7 for 
studies 5 through 13. Blood was collected in 10-mL vacutainer tubes (Monoject, Mansfield, MA) 
containing 15% EDTA. Tubes were placed immediately on ice and centrifuged within 10 to 15 
min at 1,200 × g for 20 min at 4°C. A 4-mL aliquot of plasma from each sample was placed in a 





were allowed to sit for 10 min in the centrifuge before the second centrifugation (1,200 × g for 
20 min at 5°C). An aliquot of 0.45 to 1.8 mL, depending on study, of deproteinized plasma was 
removed and placed into 1.8-mL cryovials and stored at –80°C for AA analysis (physiological 
run using norleucine as the internal standard and cation-exchange chromatography coupled with 
post-column ninhydrin derivatization and quantitation method; 982.30; AOAC, 2006; University 
of Missouri Experimental Station Chemical Laboratories). The deproteinized plasma collected 
on 2 different days in Studies 1 and 2 were composited resulting in 1 sample per cow/period. The 
deproteinized plasma collected 1.5 and 3 h after feeding in Studies 3 and 4 were composited 
using the same pooling procedure. This procedure was then repeated for deproteinized plasma 
collected at 4.5 and 6 h after feeding resulting in 2 samples per cow/period. For Studies 5 
through 13, the 4 deproteinized plasma samples collected daily were composited yielding 3 
samples per cow/period.  
Statistical Analysis 
 Dry matter intake, milk yield, concentrations and yields of milk components, and 
concentrations of plasma AA, expressed as a % of total AA (TAA), in studies 2, 5, and 7 through 
13 were collected during the week preceding the start of the experiments and were used as 
covariates in the statistical model. 
The UNIVARIATE procedure of SAS (SAS version 9.4; SAS Institute, Inc., Cary, NC) 
was used to determine outliers in each study dataset. An observation that was greater than 2.5 SD 






Data for DMI, milk yield, concentrations and yields of milk components, and plasma 
concentrations of AA (% of TAA) were analyzed using the MIXED procedure of SAS (SAS 
version 9.4) according to the following model: 
Yijkl = μ + Li +Pj + Sk + lCil  + Eijkl 
where Yijkl = is the dependent variable, μ = overall mean, Li = the fixed effect of the ith Lys 
level, Pj = the fixed effect of the jth period, Sk = the fixed effect of the kth square (Studies 6, 7, 8, 
10, and 12), l = the regression coefficient of the covariate C, Cil = the value of the covariate 
variable for the lth cow of the ith
 
level (Studies 2, 5, and 7 through 13), and Eijkl = the random 
residual error ~N (0,  ). The random effect of cow was used as the error term for the effect of 
level. Periods and squares were not retained in the final model when P ≥ 0.25. The fixed effect of 
study was analyzed, but was not significant (P < 0.62), so it was not added to the model. 
Degrees of freedom were calculated using the Kenward-Roger option of the MIXED 
procedure of SAS. Least square means were determined for Lys levels. Significant Lys level 
effects were noted at P ≤ 0.05. For Studies 1 through 5, linear and quadratic effects were 
determined using the CONTRAST statement of SAS. Significance was noted at P ≤ 0.05. No 
quadratic effects were observed for plasma Lys concentrations as a result of infused or 
supplemental RP-Lys. 
To determine the slope of the regression equation, the plasma concentration of any AA, 
on a µM basis, significantly different (P ≤ 0.05) than the same AA on the control treatment was 
removed from the TAA calculation for the control and infusion or fed Lys treatments. The AA 
used to calculate TAA were Arg, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Val, Ala, Asn, Asp, Cit, 
Cys, Gln, Glu, Gly, Orn, Pro, Ser, Tau, and Tyr. The reason for removing plasma AA that were 







with the slopes and intercepts, as well as to reduce the CV and CI, for all treatments. Lys 
concentrations increased (P ≤ 0.0001) as a result of Lys infusion in all studies. Therefore, Lys 
was removed from the TAA calculation in all studies. Using the slope ratio assay (Finney, 1978), 
the LSM generated from the MIXED procedure of SAS were subjected to the REG procedure of 
SAS to generate the linear regression lines, slopes, and r
2
.  
The following variables were regressed against the slopes to examine their impact on the 
slope: (1) Lys concentrations in total plasma AA of cows receiving the control treatment, (2) Lys 
concentration in total plasma AA at the highest infusion amount, (3) the difference between basal 
plasma Lys concentration and plasma Lys concentrations at highest Lys infusion amount, (4) 
DIM, (5) milk yield, (6) milk true protein concentration and yield, and (7) DMI.  
For studies 2, 5, and 7 through 13, percentage plasma concentrations of Lys in plasma 
total AA was analyzed using the MIXED procedure of SAS with and without the covariate 
variable to determine whether or not the covariate should be retained in the final model. This 
data was also analyzed using the MIXED procedure of SAS to determine if there were any 
significant differences between the covariate data and the 0 g/d of infused Lys. 
For studies 5 through 13, where 3 day of blood had been collected, plasma concentration 
of Lys (% of TAA-Lys) was analyzed using the REPEATED procedure with a CONTRAST 
option of SAS to determine if there were any significant differences between days for the 0 g/d 
and 60 g/d of infused Lys. 
The bioavailability of AjiPro®-L (Ajinomoto North America Inc., Fort Lee, NJ) (Study 
5) was determined herein using the following equation:   






RESULTS AND DISCUSSION 
 For the plasma AA-dose response method to be a viable method for determining Lys 
bioavailability of Lys supplements, it must first be initially demonstrated that the relationship 
between increasing amounts of absorbed Lys and plasma Lys concentrations is linear. For studies 
1 through 5, where multiple levels of Lys was infused there were linear increases in plasma Lys 
concentrations with increased levels of infused Lys (Table 4.)  Plasma Lys concentrations 
increased in a positive linear fashion (P ≤ 0.02) to incremental amounts of infused Lys in all 13 
studies (Table 4). This linear response between incremental amounts of infused Lys and plasma 
Lys concentrations is consistent with previous research (Rulquin and Kowalczyk, 2003; Borucki 
Castro et al., 2008; Hannigan et al., 2009). In Studies 7 and 8 there was also an increasing linear 
effect (P < 0.05) of additional Lys on Arg concentrations (data not shown). Lysine is a precursor 
for de novo synthesis of Arg and Pro (Bequette, 2002). However, there was no effect of 
additional Lys on plasma Pro concentrations. In these 2 studies some Lys may have been 
converted to Arg, based on the increase in Arg concentration.  
Period lengths of 14 and 21 d were used in Studies 1 and 2, respectively (Table 4). 
Similar period lengths were used for Latin square experiments in previous Lys infusion studies 
(King et al., 1991; Schwab et al., 1992b; Varvikko et al., 1999). Period lengths of 4 d were used 
in Studies 3 and 4, similar to that reported by Borucki Castro et al. (2008). Period lengths of 7 d 
were used in the remaining 9 experiments (Table 4). Benefield et al. (2009) investigated whether 
length of experimental periods (i.e., 7 and 14 d) used in a Latin square design would affect 
measurements of  animal production (i.e., DMI, milk yield, and concentrations and yields of milk 
components) when dairy cows were fed different amounts of 2 sources of RP-Met supplements. 





were largely not significant. The exception was DMI where they observed a decrease in DMI 
(Benefield et al., 2009). The authors speculated that the depressed DMI may have been 
associated with the slight sulfur smell of the RP-Met supplements that were used. The RP-Lys 
supplements used in the current study were readily consumed by the cows in most feeding events 
indicating little negative impact on palatability and DMI. It is noteworthy that Rulquin and 
Kowalczyk (2003) observed that steady state conditions for appearance of the AA in the blood 
were reached after 4 d of treatment. There may be significant diurnal variations for the AA, but 
overall mean concentrations do not appear to change after day 4 of providing treatments. Based 
on the results of Benefield et al. (2009) and Rulquin and Kowalczyk (2003) and our first 
experiments, we concluded that 7 d experimental periods were acceptable in Latin square studies 
in which cows are fed RP-Lys and Met supplements. Therefore, we used 7-d experimental 
periods in studies 5 through 13. 
To further assess if the period lengths of 7 days with 4 days of adaptation and 3 days for 
measurement were adequate, the studies where covariate data (3 d prior to the start of the study) 
were collected were used to compare the concentration of Lys in the covariate plasma sample to 
the concentration of Lys in the control (0 g/d of infused Lys) plasma samples. There were no 
differences between plasma Lys concentrations for the covariate periods and control treatments 
(Table 5). This is an important observation given the short duration of the experimental periods. 
We also compared d-5, 6, and plasma Lys data for control and 60 g/d Lys infusion 
treatments to see if there were any changes, the results are provided in Table 6. In none of the 9 
studies was there a significant linear effect of day. If carry-over effects had been observed, linear 
decreases in plasma Lys concentrations would have been expected as cows progressed from the 





plasma Lys concentrations would have been expected as cows progressed from the control 
treatment to the 60 g/d of infused or fed Lys treatment. Since effects of day on plasma Lys 
concentration were not observed, we conclude that the period lengths were adequate. However a 
significant quadratic effect was observed for plasma Lys concentrations for both 0 and 60 Lys 
treatments in study 7 and 60 Lys treatment for study 9. For study 7 concentrations were higher 
on day 6 for the 0 treatment as compared to day 5 and lower on day 6 for the 60 Lys treatment 
than for day 7. For study 9 concentrations were higher on day 6 for the 60 Lys treatment 
compared to day 5 and 7. There was no difference in the study methodology of these 2 studies 
compared to the other 7, so why this increase of decrease on day 6 cannot be determined. 
When determining the values to use for slope determination, Lys was the only AA 
removed from the calculation of TAA concentration, whereas Lys was expressed as Lys (% of 
TAA – % Lys). As discussed earlier, this calculation resulted in decreased SE around the slopes 
and intercepts, reduced CI for the slopes and intercepts, and reduced CV for the regression 
models for all studies except 11 and 12 where SE for the slopes were the same when expressed 
as either Lys (%TAA) or Lys (% of TAA – % Lys; Table 7).  
The intercepts of the regressions between incremental amounts of infused Lys and plasma 
Lys concentrations were significantly lower in cows fed Lys deficient diets (Studies 1 and 2) 
than in cows fed Lys adequate diets (Studies 3 through 13; Table 4). Within the studies in which 
cows were fed Lys adequate diets, the intercepts of Studies 3 and 4 were greater than the 
intercepts of Studies 5 through 13. The greatest quantity of infused Lys occurred in studies 3 and 
4. Studies 3 and 4 also enrolled late lactation cows with the lowest milk yield across all 





able to determine if there was an effect of treatments on milk components percentages and 
yields. 
The coefficient of determination for 12 of the 13 studies ranged from 0.93 to 0.99, 
whereas that of Study 2 was 0.83 (Table 4). The range of the doses of Lys infusion was 
narrowest in Study 2 (from 0 to 32 g/d), thus making the regression line of this experiment more 
susceptible to changes in status of plasma Lys concentration. Blum et al. (1985) suggested that 
an increase in plasma concentration of 3-methylhistidine could be used as an indicator of muscle 
protein degradation. We observed a positive linear increase (P ≤ 0.025) in 3-methlyhistidine 
(data not shown) as the amount of infused Lys increased in early-lactation dairy cows (Study 2).  
Therefore, Lys mobilization from muscle protein and the consequent increase in plasma 
concentration of Lys may have also impacted the relationship between infused Lys and plasma 
Lys concentration. Therefore, in studies measuring RP-Lys supplement bioavailability, cows 
should be assigned that after peak lactation to avoid considerable contributions of degraded 
muscle protein to the plasma Lys pool. 
According to the NRC (2001), when Lys as a % of MP is 6.83% or greater it is 
considered to be adequate in Lys. In Study 2, Lys as a % of MP for the control treatment was 
5.52% and for the 32 g/d Lys infusion treatment it was 6.55%. Although diets in Study 1 were 
also formulated to be Lys deficient, actual Lys as a % of MP was 5.05% for the control 
treatment, 6.76% for the 49.5 g/d infused Lys treatment and 7.15% for the 66 g/d Lys infusion 
treatment. Thus, in Study 1 the Lys requirement was met or exceeded the recommended 
concentration Lys as a % of MP with the infused Lys treatments. By not meeting the 
recommended concentration of Lys as a % of MP in the control treatments, Lys was likely 





result, affected the slope of the regression line. Borucki Castro et al. (2008) fed a Lys and Met 
adequate diet and obtained a linear response in plasma Lys concentration, suggesting that Lys 
adequate diets are favored over Lys deficient diets when determining the bioavailability of RP-
Lys supplements. 
Rulquin and Kowalczyk (2003) and Hanigan et al. (2009) conducted experiments to 
determine the bioavailability of RP-AA supplements using 1 set of cows to determine the slope 
for infusion and a second set of cows to determine the slope for the RP-AA supplements. We 
chose Studies 8, 9, and 10, which were all conducted in the same year with cows fed forage 
sources harvested in similar dates to test our hypothesis that all treatments should be included in 
the same Latin square. We observed that the slope of the regression line was greatest in Study 8, 
intermediate in Study 10, and least in Study 9 (0.037, 0.035, 0.032, respectively, Table 4). Thus, 
the differences in these slopes reinforced that all treatments should be present in the same Latin 
square to minimize the likelihood to over- or underestimate the bioavailability of RP-Lys 
supplements tested due to large variances in plasma Lys concentration in different groups of 
cows.  
The mean and range of different variables that were regressed against their respective 
slopes are presented in Table 8. The ranges of the individual variables were large, indicating that 
a wide spectrum of animal parameters were considered when conducting regression analysis; for 
instance, DIM ranged from 60 to 335 d. Table 8 also shows the coefficients of determination that 
resulted from the regression of the slope against different variables. The r
2
 for the difference 
between the plasma Lys concentration of the control treatment and the greatest infusion amount 
was 0.82, which was not surprising since a greater difference in plasma Lys concentrations 
results in a greater slope. The r
2





averaged 0.32 and that for the remaining variables
 averaged ≤ 0.009. These low r2 (i.e., ≤ 0.009) 
indicate that the control basal concentrations of plasma Lys, DIM, milk yield, DMI, and milk 
protein content and yield had minimal impact on the slope of the regression between incremental 
amounts of infused Lys and plasma Lys concentration.  
Studies 2, 5, and 7 through 13, in which covariate data were obtained, were used to 
determine whether the covariate term was significant in the final statistical model (Table 9). The 
covariate term of Studies 2, 5, and 11 were not significant, and the SE of Studies 5 and 11 were 
not improved when the covariate term was retained in the final model. With the exception of 
Study 9, all remaining experiments with significant covariate terms (i.e., Studies 7, 8, 10, and 13) 
were conducted as replicated Latin squares. These results appear to indicate a larger animal 
variation in replicated versus single Latin square experiments. Overall, we recommend the 
collection of covariate period data of 7 days and statistical analysis should be used to determine 
if the covariate term should be maintained in the final model.  
Expressing plasma Lys as a % of TAA-Lys before calculating bioavailability is 
recommended because it reduces the SEM and CI associated with the bioavailability. Table 10 
reports the bioavailabilities of 3 RP-Lys supplements (RP-LysA, RP-LysB, and RP-LysC) 
determined in Study 12, using plasma Lys concentrations based on absolute (µM) or as a 
percentage of total AA – Lys (%TAA) basis. There is no difference between the bioavailability 
calculated using µM or %TAA, RP-LysA 17.3 and 17.4%, RP-LysB 23.3 and 24.6 and RP-LysC 
27.9 and 28.8, respectively. When bioavailabilities are expressed as %TAA the SEM are lower, 






Limitations of this approach were that in all 13 studies conducted, the SE of the 
observations used to determine the slopes of the infused treatments were greater than those used 
to determine the slopes of fed amounts of Lys. These greater SE could be partly explained by 
differences in the types of pumps used as well as the differences in the cassettes that were used 
on the pumps, which together may have slightly changed the planned flow rate. In addition, the 
infusion of Lys-HCl was discontinued during milking times for approximately 90 min daily and 
likely contributed to additional variation. Even though the infusion lines were checked for proper 
position in the abomasum the day before infusions started and once or twice weekly thereafter, it 
cannot be disregarded that lines may have been removed or partially removed from the infusion 
site for short or long periods of time. This could also contribute to infusion variation. However, 
if an infusion line was found to be outside of the abomasum, it was immediately repositioned and 
the event promptly recorded. Another source of variation is the assumption that the efficiency of 
use of Lys is the same on the control treatment and the infusion treatments if Lys was the first 
limiting AA in MP. This assumption may be incorrect because metabolism of Lys may increase 
and the efficiency of use of Lys may decrease with increasing Lys supply. Borucki Castro et al. 
(2008) used the whole body Lys flux technique in lactating dairy cows using a pulse dose of L-
[2–15N] Lys and the plasma Lys 15N decay curve. These authors assumed that whole body 
protein degradation is constant and that changes in whole body Lys flux are due to differences in 
intestinal supply and absorption of Lys. For instance, Borucki Castro et al. (2008) demonstrated 
that when a Lys adequate diet was fed and 70 g/d of Lys was infused into the omasum, the whole 
body Lys flux increased by approximately 70 g/d compared with the control treatment (solvent-





difference between treatments without apparent loss of the infused Lys dose. This may also 
indicate that efficiency of use of Lys may not decrease with increasing supplies of Lys. 
Since the bioavailability of RP-Lys supplements can be reduced after mixing in TMR, we 
recommend mixing the RP-Lys supplements with a small amount of TMR approximately 8 to 12 
h before feeding in order to mimic normal feeding conditions. In normal feeding conditions, RP-
Lys supplements are mixed with TMR and the TMR can sit in feed bunks for 0 to 24 h while 
cows consume the ration. Ji et al. (2015) conducted an in vitro experiment to determine the effect 
of increasing times of exposure of RP-Lys supplements in high and low moisture TMR on the 
release of Lys from RP-Lys supplements. Results indicate that the physical contact with TMR 
causes loss of Lys from the supplements and the extent of loss differed among supplements. 
Therefore, to measure accurate bioavailabilities, RP-Lys supplements should be stored in TMR 
for a minimum of 8 h before each feeding to take into account potential loss in the TMR. 
To demonstrate the utility of the plasma free AA dose-response technique as a viable 
methodology for determining the bioavailability of an RP-Lys supplement we present the results 
of an evaluation of AjiPro-L (Ajinomoto North America Inc., Fort Lee, NJ) shown in Figure 15. 
The resulting slopes for infusion and AjiPro-L were 0.0183 and 0.0068, respectively. The 
calculated bioavailability for AjiPro-L was 37.2% (Figure 15). This value is similar to the 
company reported bioavailability of 40% for the same RP-Lys supplement reported by 
Ajinomoto (I. Shinzato, Ajinomoto Heartland, Inc., Chicago, IL, personal communication). The 
highly protected L-Arg procedure as described in Swanepoel et al. (2010) and Robinson et al. 
(2011) was used by Ajinomoto to determine ruminal escape of AjiPro-L. In the first step of this 
method, known amounts of the highly protected L-Arg and AjiPro-L were fed to lactating 





RP-Lys through the rumen and therefore the particle size and specific gravity of both were the 
same. Duodenal samples were then collected and the concentrations of Lys and Arg were 
determined. It was assumed that 100% of the L-Arg fed escaped ruminal degradation, and the 
ruminal escape was calculated as the ratio of Lys to Arg area under the curves. In the second step 
of the method, the post ruminal release of Lys was determined, which involved feeding a known 
amount of AjiPro-L to lactating Holstein cows and collecting feces for 72 h. The amount of free 
L-Lys was determined in the fecal samples and it was assumed to be originated from the 
indigestible portion of AjiPro-L. With this value, the amount of Lys released post-ruminally was 
finally determined. As with any procedure that involves 2 separate steps, there are inherent 
limitations and errors resulting in over- or underestimation of bioavailability values of RP 
supplements tested. In our plasma free AA dose-response technique, the infusion of Lys-HCl and 
feeding of the RP-Lys supplements tested were conducted simultaneously in the same cows 
consequently mitigating the variation associated with 2-step procedures. 
Our general recommendations for using the plasma dose response technique are 
presented in Table 11. 
CONCLUSIONS 
The results from the studies presented herein and from previous research support 
observations that a positive linear relationship exists between plasma Lys concentrations and 
increasing doses of infused Lys. Due to the animal-to-animal variation that exists in the basal 
concentrations of plasma free Lys, it is important that all Lys treatments (i.e., infused and fed) 
are included in the same Latin square when determining the Lys bioavailability of RP-Lys 
supplements. The collection of covariate data including DMI, milk yield, concentrations and 





the experiment is recommended, particularly in replicated Latin square designs. The dataset 
should be analyzed with and without the covariate data to ensure the need to retain the covariate 
term in the final statistical model in each individual study. We also recommend mixing the RP-
Lys supplements with a small amount of TMR approximately at least 8 h before feeding in to 
take into account any effects that the TMR has on the supplements. It is also recommended that a 
minimum of 4 days be used for adaptation to treatments before blood samples are obtained. We 
also recommend taking blood samples for a minimum of 3 consecutive days so that outlier data 
can be determined. Express plasma Lys as a % of TAA-Lys before calculating bioavailability. 
Finally, the authors strongly recommend the acceptance of the plasma free AA dose-response 









Table 2. Ingredient composition (% DM) of the basal diets, DMI, milk yields and NRC evaluation of the fed control diets using post 
study means. 
 Study  
Ingredient 1 2 3 4 5 6 7 8 9 10 11 12 13 
Corn silage, mature 39.4 32.9 36.7 36.7 36.6 36.1 36.0 34.1 34.0 33.9 34.9 32.4 32.4 
Mixed mostly grass silage, mid 9.92 10.9 12.1 12.1 13.7 13.9 13.9 13.9 14.4 14.5 14.1 16.3 16.4 
Legume hay, mid-maturity – 7.20 5.44 5.44 2.70 2.81 – – – – – – – 
Wheat straw – 1.03 0.93 0.93 – – – – – – – – – 
Steam flaked corn – – 3.76 3.76 4.25 4.33 4.46 4.67 4.58 4.57 4.58 4.21 4.22 
Corn meal 26.9 21.8 9.73 9.73 11.0 11.2 11.6 12.1 11.9 11.9 11.9 11.5 11.5 
Corn distillers grains w/solubles – 4.98 0.97 0.97 0.89 0.88 1.04 1.04 1.08 1.08 1.11 1.12 1.11 
Corn gluten meal 7.55 2.51 – – – – – – – – – – – 
Corn gluten feed 11.5 14.1 – – – – – – – – – – – 
Citrus pulp – – 7.12 7.12 8.07 8.24 8.48 8.85 8.71 8.70 8.71 8.43 – 
Beet pulp – – – – – – – – – – – – 8.44 
Soybean meal, solvent extracted – – 9.38 9.38 8.43 8.57 9.89 9.89 10.1 10.1 10.5 10.8 10.8 
Soy hulls – – 3.01 3.01 3.39 3.46 3.57 3.74 3.65 3.65 3.67 3.55 3.55 
Canola meal, solvent – – 2.96 2.96 2.67 2.72 3.13 3.13 3.21 3.21 3.33 3.39 3.39 
Molasses, sugar cane – – 1.06 1.06 1.19 1.20 1.24 1.32 1.29 1.29 1.29 1.24 1.23 
ProvAAL Elite
1,2
 – – 2.26 2.26 2.20 – – – – – – – – 
ProvAAL Basic
1
 – – – – – 2.21 2.26 2.26 2.21 2.21 – – – 
ProvAAL Lysine
1
 – – – – – – – – – – 1.67 1.98 1.77 
Smartamine M
3
 0.08 0.08 – – – 0.12 0.11 0.08 0.07 – 0.07 0.07 0.07 
MetiPEARL
4 – – – – – – – – – 0.20 – – – 
Urea 0.50 0.49 0.22 0.22 0.32 0.29 0.25 0.25 0.24 0.24 0.29 0.33 0.24 
BergaFat F-100
5 
0.75 0.74 0.93 0.93 1.15 0.83 0.83 1.41 1.37 1.37 1.00 1.79 2.04 
Mineral/vitamin mix 3.44 3.30 3.46 3.46 3.43 3.11 3.23 3.27 3.18 3.05 2.77 2.89 2.82 
              
DMI, kg/d 24.1 24.3 22.9 21.8 22.1 21.7 24.0 24.8 24.3 22.6 22.9 24.5 21.6 
Milk yield, kg/d 44.4 40.4 33.3 22.6 40.6 34.6 46.1 39.5 44.5 40.8 38.3 46.0 29.2 
              
NELbalance, Mcal/d -2.4 0.4 0.2 5.4 -3.6 -3.43 -4.2 0.4 -4.8 -2.3 -1.3 -2.3 2.3 








RUP, % DM 7.3 6.1 6.9 6.8 6.1 6.4 6.7 7.0 6.8 6.8 6.2 6.8 6.5 
RDP balance, g/d -192 357 141 136 -40 -1 11 95 82 58 24 156 55 
RUP balance, g/d 187 42 -32 440 -247 -107 -218 149 -181 4 -154 -12 279 
MP-Lys, % MP 5.05 5.52 6.78 6.81 6.80 6.60 6.60 6.43 6.53 6.58 6.67 6.51 6.68 
MP-Met, % MP 2.35 2.43 2.06 2.06 2.08 2.37 2.26 2.08 2.08 2.17 2.13 2.01 2.09 
MP-Lys, g/d 143 144 178 170 162 158 181 187 182 173 169 185 163 
MP-Met, g/d 66 64 54 52 50 57 62 60 58 57 54 57 51 
1
Perdue AgriBusiness (Salisbury, MD). 
2
ProvAAL Elite contains Smartamine M. 
3
Adisseo USA Inc., Alpharetta, GA. 
4
Kemin Industries Inc., Des Moines, IA. 
5













Ingredient DM          CP      NDF      ADF     Lignin   Crude  fat        Ash 
     Lys  
   (% CP) 
      Met  
    (%CP) 
Corn silage 31.2 ± 1.9 7.7 ± 0.5 42.9 ± 4.3 26.1 ± 2.7 3.3 ± 0.8 3.7 ± 0.6 3.9 ± 0.5 2.82 ± 0.3 1.53 ± 0.2 
Grass silage
1
  35.2 ± 3.3 15.6 ± 1.6 57.3 ± 3.9 39.2 ± 2.0 6.6 ± 1.2 4.7 ± 0.9 9.5 ± 0.9 4.33 ± 0.3 1.39 ± 0.1 
Legume hay 89.0 ± 3.7 19.2 ± 1.7 42.2 ± 3.3 33.1 ± 2.8 6.8 ± 1.0 1.9 ± 0.3 10.6 ± 0.6 5.32 ± 0.8 1.48 ± 0.2 
Wheat straw 91.5 ± 0.2 4.7 ± 0.1 81.1 ± 2.8 56.6 ± 1.5 8.7 ± 0.9 1.1 ± 0.4 8.9 ± 2.0 3.08  ± 0.1 1.10 ± 0.1 
Steam flaked corn 88.6 ± 2.8 7.9 ± 0.7 10.0 ± 2.2 3.7 ± 0.9 1.4 ± 0.5 3.5 ± 0.5 1.4 ± 0.2 3.35 ± 0.3 1.93 ± 0.1 
Corn meal 89.8 ± 1.8 8.2 ± 0.8 10.0 ± 0.9 3.8 ± 0.6 1.2 ± 0.4 3.8 ± 0.3 1.4 ± 0.2 3.60 ± 0.4 1.96 ± 0.2 
Corn DDGS
2
 90.9 ± 1.6 29.9 ± 1.4 34.4 ± 3.4 15.2 ± 1.84 4.2 ± 1.3 12.2 ± 2.3 6.7 ± 0.7 3.57 ± 0.2 1.97 ± 0.1 
Corn gluten meal 91.4 ± 1.2 67.3 ± 0.9 5.2 ± 1.1 3.6 ± 0.6 2.2 ± 0.3 2.8 ± 0.3 4.2 ± 1.5 1.81 ± 0.1 2.46 ± 0.1 
Corn gluten feed 90.6 ± 4.7 28.0 ± 7.8 37.8 ± 5.4 13.5 ± 1.6 1.4 ± 0.7 4.3 ± 0.9 5.6 ± 0.6 3.20 ± 0.1  1.51 ± 0.1 
Citrus pulp 91.8 ± 1.1 6.6 ± 0.5 24.0 ± 1.3  21.4 ± 1.1 2.0 ± 1.0 2.7 ± 0.3 8.2 ± 0.6 3.20 ± 0.5 1.05 ± 0.1 
Soybean meal
3
 91.0 ± 2.1 52.3 ± 0.9 12.0 ± 2.1  8.0 ± 1.1 1.2 ± 0.4 1.2 ± 0.2 7.2 ± 0.9 6.37 ± 0.2 1.34 ± 0.1 
Beet pulp 91.0 ± 0 7.1 ± 0 33.0 ± 0 29.2 ± 0 4.5 ± 0 1.0 ± 0 12.5 ± 0 6.34 ± 0 1.33 ± 0.1 
Soy hulls 91.7 ± 2.0 11.5 ± 1.7 68.4 ± 4.2 48.1 ± 1.9 3.0 ± 0.9 2.2 ± 0.7 5.1 ± 0.5 6.93 ± 0.6 1.08 ± 0.1 
Canola meal
4 
91.7 ± 1.4 41.6 ± 1.8 31.9 ± 2.7 22.8 ± 1.9 10.1 ± 0.9 3.9 ± 0.5 7.5 ± 0.3 5.66 ± 0.2 1.96 ± 0.1 
Molasses
5
 75.9 ± 1.0 7.3 ± 1.6 – – – 1.9 ± 0.7 15.5 ± 2.4 0.43 ± 0.1 0.11 ± 0.1 
ProvAAL Elite
6
 97.1 ± 0 87.7 ± 0 – – – 3.9 ± 0 5.41 ± 0 7.36 ± 0 4.02 ± 0 
ProvAAL Basic
7
 93.6 ± 1.8 90.8 ± 2.3 – – – 3.8 ± 1.2 5.0 ± 0.8 7.24 ± 0.3 1.14 ± 0.1 
ProvAAL Lysine
8
 94.5 ± 0.7 88.3 ± 2.6 – – – 3.3 ± 0.1 10.3 ± 1.9 6.47 ± 0.1 0.86 ± 0.1 
1
Mixed mostly grass silage. 
2
Corn distillers grain with solubles. 
3
Soybean meal, 48%CP. 
4




Perdue AgriBusiness (Salisbury, MD). Contains blood meal, feather meal, 2-hydroxy-4-(methylthio) butanoic acid and 2.7% 
Smartamine M. 
7
Perdue AgriBusiness (Salisbury, MD). Contains blood meal, feather meal, and 2-hydroxy-4-(methylthio) butanoic acid. 
8
Perdue AgriBusiness (Salisbury, MD). Contains blood meal and feather meal.  
  






Table 4. Experimental design conditions, slope, intercept, P-value for linear contrast, and r
2
 for the 13 studies that were generated 






























Lys deficient diet 






 0.002 0.97 0.142 




 0.009 0.84 0.238 
 
Lys adequate diet 




 0.003 0.96 0.230 




 0.005 0.93 0.238 




 0.003 0.97 0.151 




 0.002 0.98 0.173 




 0.004 0.95 0.283 
8
2 
2 - 3 × 3 179 ± 
123 




 0.002 0.99 0.136 
9
2 
6 × 6 189 ± 
125 




 0.003 0.95 0.256 
10
2 




 0.001 0.99 0.104 




 0.001 0.99 0.090 




 0.001 0.99 0.041 




 0.002 0.97 0.158 
1
Lys g/d infused, per 24.6 kg DMI for Study 1, per 24.9 kg DMI for Study 2 and per 22.7 kg DMI for studies 3 through 13. 
2
Slopes for these studies when analyzed separate from the other slopes, differ from each other (P < 0.04).  
a-c
Means in the same column differ (P < 0.05).
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Table 5. Percentage Lys in plasma total AA of cows three day prior to start of study (covariate 
period) and three day of blood sampling during the study 0 g/d Lys treatment 
 3 Days Prior  3 Days of sampling  P-value 
Item Day 1 Day 2 Day 3  Day 1 Day 2 Day 3 SEM Day 
Study 5 3.48 3.50 3.73  3.74 3.62 3.67 0.248 0.351 
Study 7 3.56 3.56 3.66  3.66 3.96 3.74 0.119 0.127 
Study 8 3.56 3.70 3.52  3.68 3.62 3.60 0.212 0.430 
Study 9 3.42 3.42 3.47  3.63 3.57 3.64 0.169 0.123 
Study 10 3.50 3.50 3.56  3.56 3.65 3.64 0.184 0.299 
Study 11 3.70 3.81 3.76  3.88 3.85 3.75 0.101 0.244 
Study 12 3.51 3.55 3.62  3.57 3.52 3.61 0.196 0.842 




Table 6. Effect of time on plasma Lys concentration (% of TAA) on the last 3 days of treatments 
for 0 and 60 g/d of abomasal infused Lys. 
 Plasma Lys concentration, 
% of TAA 
 P-value 
Item Day 5 Day 6 Day 7 SEM Day Linear Quadratic 
Study 5        
   Lys 0 g/d 3.74 3.62 3.67 0.252 0.771 0.665 0.579 
   Lys 60 g/d  4.99 5.02 4.62 0.341 0.294 0.208 0.341 
Study 6        
   Lys 0 g/d 3.34 3.42 3.50 0.251 0.526 0.265 0.997 
   Lys 60 g/d  4.91 4.94 5.12 0.524 0.783 0.525 0.787 
Study 7        






0.154 0.098 0.551 0.039 






 0.308 0.046 0.127 0.043 
Study 8        
   Lys 0 g/d 3.69 3.61 3.60 0.252 0.730 0.498 0.666 
   Lys 60 g/d  5.69 6.06 5.86 0.419 0.530 0.609 0.325 
Study 9        
   Lys 0 g/d 3.61 3.57 3.63 0.200 0.807 0.846 0.545 






0.288 0.470 0.811 0.017 
Study 10        
   Lys 0 g/d 3.56 3.65 3.64 0.179 0.318 0.216 0.384 
   Lys 60 g/d  5.75 5.80 5.64 0.236 0.713 0.595 0.546 
Study 11        
   Lys 0 g/d 3.88 3.85 3.76 0.110 0.387 0.206 0.650 
   Lys 60 g/d  5.52 5.36 5.55 0.344 0.467 0.850 0.240 
Study 12        
   Lys 0 g/d 3.58 3.52 3.61 0.179 0.624 0.704 0.376 
   Lys 60 g/d  5.14 5.10 5.20 0.181 0.921 0.813 0.740 
Study 13        
   Lys 0 g/d 4.05 4.04 4.10 0.163 0.847 0.650 0.729 
   Lys 60 g/d  5.10 5.46 5.37 0.326 0.691 0.531 0.546 
Overall mean        
   Lys 0 g/d 3.71 3.74 3.74 0.080 0.817 0.587 0.738 







Table 7. Standard errors and confidence intervals for the slopes and intercepts and coefficient of variation for the regression model for 
the 13 studies when Lys was expressed as %TAA or %TAA-Lys 
 Lys (%TAA)  Lys (%TAA-Lys) 





































































































































Table 8. Mean, range, and coefficient of determination of measured variables for the studies that were regressed against the slopes 
Variable Mean Range SEM      r
2
 
Difference between plasma Lys conc. of basal and 









Plasma Lys conc.at highest infusion amount, % of TAA 5.28 2.53 to 7.51 0.990 0.315 
Basal plasma Lys conc., % of TAA 3.64 1.83 to 5.21 0.623 0.088 
DIM 180 60 to 335 65.8 0.003 
Milk yield, kg/d 39.0 11.9 to 61.9 9.65 0.002 
Milk true protein, % 3.09 2.54 to 3.72 0.260 0.003 
Milk true protein yield, kg/d 1.2 0.4 to 1.7 0.23 0.001 
DMI, kg/d 23.1 15.6 to 28.8 2.69 0.003 
BW 700 571 to 846 650 0.000 
BCS 3.18 2.08 to 4.25 0.442 0.017 
Milk fat, % 3.78 2.54 to 4.74 0.501 0.000 













2 Yes 0.33 0.25 
 No  0.27 
5 Yes 0.27 0.16 
 No  0.16 
7 Yes 0.05 0.15 
 No  0.16 
8 Yes <0.0001 0.11 
 No  0.32 
9 Yes 0.05 0.17 
 No  0.21 
10 Yes <0.0001 0.09 
 No  0.17 
11 Yes 0.92 0.24 
 No  0.20 
12 Yes 0.09 0.09 
 No  0.10 
13 Yes 0.03 0.13 




Table 10. Plasma Lys concentrations for study 12 expressed on an absolute (µM) and as a 
percentage of total AA minus Lys (% TAA). 
 µM basis  % TAA basis 
Item Slope SEM Bioavailability (CI)  Slope SEM Bioavailability (CI) 
  Infusion 0.637 0.083 -  0.023 0.004 - 
  RP-Lys A 0.110 0.092 17.3
b
 (9.6 - 25.0)  0.004 0.005 17.4
b
 (13.8 - 21.0) 
  RP-Lys B 0.149 0.110 23.3
ab
 (14.4 - 32.2)  0.006 0.006 24.6
a
 (21.2 - 27.7) 
  RP-Lys C 0.178 0.068 27.4
a
 (22.1 - 32.7)  0.007 0.004 28.8
a
 (25.5 - 32.1) 
a,b





Table 11. Recommended protocol for determining bioavailability of rumen protected amino acid 
supplements using the plasma free amino acid dose response technique 
 
Experimental design 
Latin square with all experimental treatments in the same 
square. This is important because of animal variation (i.e., 
differences in the magnitude of plasma Lys responses to 
similar amounts of supplemental Lys).  
Animals Rumen-cannulated lactating dairy cows, preferably at similar 
stages of lactation and DMI. DIM should be >70-90 DIM to 
avoid negative protein balance. A replicate the study is best. 
 
Basal diet 
A TMR balanced for energy and nutrients. Feed 3 times per 
day at 8-h intervals. 
 
Covariate period 
Measure DMI and milk yield daily starting 7 d before start of 
experiment and collect milk and blood samples starting 3 d 
before for purpose of obtaining baseline data for all 
experimental measurements. This data can also be used to 
detect any if there is any carry over. 
 
Treatments 
A minimum of 2 level of abomasally or intestinally infused 
Lys and 2 levels of fed Lys from the test supplements (e.g., 0 
and 60 g/d).  Can use other amounts such as 3 levels of 
abomasally or intestinally infused Lys and 3 levels of fed 
Lys from the test supplements (e.g., (0, 30, and 60 g/d)  
 
Infused treatments 
Mix and dissolve in a minimum of 4 L of water; infuse 
continuously into abomasum or duodenum adjusting pump 





Mix with 1.5 kg of TMR, place in plastic container with lids, 
and store at 4°C for 8 h before feeding. To ensure complete 
consumption, place the TMR/RP-Lys mix in 25 L fed tubs 
and feed 30 min before each feeding. If the mix is not 
completely consumed within 15 min, recover what is not 
consumed and put in rumen.  
Period length Minimum of 7 d 
 
Blood sampling  
Collect 4 blood samples (coccygeal vein or jugular vein), at 
2-h intervals following the morning feeding (2, 4, 6, and 8h 
after feeding), from each cow on the last 3 d of the covariate 
period and the last 3 d of each experimental period.  
 
Blood handling, processing 
and analysis 
Collect blood in 10-mL vacutainer tubes appropriate for the 
amino acid analysis being performed. Place immediately into 
an ice bath and centrifuge within 15 min at 1,200 x g for 20 
min at 5°C. If analysis calls for deproteinized plasma pipette 
4 mL of supernatant into a labeled glass test tube containing 
1.0 mL of 15% SSA. Allow tubes to sit for 10 min in the 
cold centrifuge before spinning at 1,200 x g for 20 min at 
5°C. Remove a 0.45-mL aliquot of deproteinized plasma and 
place into 1.8-mL cryovial and store at -80°C for AA 
analysis. If analysis calls for plasma remove a 0.45-mL 
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aliquot of plasma and place into 1.8-mL cryovial and store at 
-80°C for AA analysis. Do not pool the days together. 
Outlier analysis of plasma AA 
data 
Conduct a univariate analysis to determine outlier Lys AA 
concentrations and values within cows for plasma Lys (% of 
total AA). Consider any observation greater than 2.5 
standard deviations from the mean as an outlier. Determine 
outliers both by level and by cow. This is to ensure that 
values from a cow with lower or higher overall values are 
not removed from the dataset.  
Statistical analysis Conduct a repeated measures analysis to determine if day is 
significant. If it is not significant, average the 3 days together 
and conduct regression analysis.  If it is significant than use 
the repeated measures analysis to determine means. 
Calculation of Lys 
bioavailability values 
Slope of the RP-AA fed regression line 
Slope of the Lys infusion regression line  





Figure 15. Response of plasma Lys concentrations to graded levels of infused Lys-HCl (♦) and 
AjiPro
®
-L (■) in lactating dairy cows fed a Lys adequate diet. There was a linear effect on Lys 
plasma concentration for Lys infusion [Y = 3.79 + 0.0183x; P < 0.0001, SE slope = 0.003, SE 
intercept = 0.12, R
2
 = 0.97] and AjiPro-L [Y = 3.74 + 0.0068x; P = 0.001, SE slope = 0.002, SE 
intercept = 0.06, R
2





Using the plasma free amino acid dose-response technique to determine the bioavailability 
of Met in a RP-Met supplement 
 
INTRODUCTION 
Several in vitro and in situ methods have been used for determining the concentration of 
Met in rumen-protected (RP)-Met products. However, these techniques have several 
shortcomings including lack of exposure of RP-Met supplements to in vivo influences of intake, 
mastication, rumination, digesta passage, and absorption. Another crucial shortcoming is the 
assumption that disappearance from in situ bags equals digestion and absorption, which may not 
always be true. It is also important to note that the use of the mobile bag technique with recovery 
of bags in the feces likely overestimates the bioavailability of RP-Met supplements due to their 
exposure to hindgut fermentation.  
The plasma free AA area-under-the curve methodology as described by Graulet et al. 
(2005) has been used to quantify the content of several RP-Met supplements (e.g., Devillard et 
al., 2011; Faivre et al., 2013). Specifically, jugular blood samples are taken several times to 
determine baseline concentrations of plasma Met followed by a pulse ruminal dose of the test 
RP-Met product and additional blood samples continue to be taken  until Met concentrations 
return to baseline values. The AUC is calculated from measured Met concentrations.  
Bioavailability, in turn, was calculated with the equation (MetDi = 18.1943 × ln (1 + 
AUC/520.1822) from Graulet et al. (2005) which was derived by modeling the relationship 
between plasma Met response in term of AUC (area under the curve) and digestibleMet values 
supplied as increasing doses of Smartamine M.  A bioavailability of 80% was used for 
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Smartamine M. While it was clear from earlier research that the AUC technique differentiates 
product bioavailabilities of different Met supplements (e.g., Robert et al., 1997), a concern has 
been that animals receive large single doses of the test product not commonly encountered in 
typical feeding conditions and that estimates of bioavailability might be  dose-dependent.  
Indeed, this was shown by the curvilinear relationship between the plasma Met AUC responses 
and increasing ruminal dosages of Smartamine M.  A similar conclusion was reached by Evans 
et al. (2013) who reported Lys bioavailabilities of 58, 67, and 70% with ruminal pulse doses of 
37.5, 50, and 62.5 g/d of Lys from Megamine-L
®
 (Princeton, NJ, USA). .  
The plasma free AA dose-response technique assumes that a positive linear relationship 
exists between plasma concentrations and increasing amounts of absorbed Met over the test 
range of product evaluation. While the number of experiments testing the bioavailability of RP-
Met products using the plasma free AA dose-response technique is limited (Rulquin and 
Kowalczyk, 2003), published results indicate that a linear relationship exists between increasing 
amounts of absorbed Met and plasma free Met concentrations. For instance, the plasma 
concentration of Met increased linearly across a range of infused amounts of Met and 
supplemental RP-Met in both weaned calves fed complete pelleted starter rations (Schwab et al., 
1982; Donahue et al., 1985) and lactating dairy cows fed TMR (Schwab et al., 1992; Ordway et 
al., 2013). Because of this demonstrated response of linearity between plasma Met 
concentrations and increasing amounts of absorbed Met, we believe that the plasma free AA 
dose-response technique is a more appropriate in vivo approach for determining the 
bioavailability of RP-Met products.  
The objectives of this experiment were: 1) to confirm linearity in plasma Met response 
with up to 24 g/d of DL-Met by abomasal infusion or up to approximately 24 g/d of DL-Met by 
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feeding 30 g/d of supplemental Met from a RP-Met product (i.e., Smartamine® M), 2) to 
determine if plasma concentrations of Met or total sulfur AA (TSAA) is the more precise 
response parameter, 3) to determine if expressing plasma concentrations of Met and TSAA as 
percentages of total AA concentrations (with concentrations of Met or TSAA subtracted from 
total AA concentrations, respectively) would reduce variability and increase precision of 
estimating Met bioavailability, and to 4) obtain a first estimate of the bioavailability of Met in 
Smartamine M . We hypothesized that there is linearity between plasma Met concentrations and 
incremental amounts of fed or infused Met, andthat using plasma concentrations of TSAA and 
expressing those concentrations  as a percentage of TAA would increase the precision of Met 
bioavailability estimates. 
 
MATERIALS AND METHODS 
All procedures related to animal care were conducted with approval of the University of 
New Hampshire Institutional Animal Care and Use Committee (IACUC no. 130701 and 
140403). The experiment was conducted at the University of New Hampshire Fairchild Dairy 
Teaching and Research Center (Durham, NH). 
 
Experimental Design and Treatments 
Ten ruminally-cannulated Holstein cows averaging (mean ± SD) (147 ± 47 DIM, 710 ± 
77 kg of BW, and 3.00 ± 0.35 BCS) were fed a Met-deficient basal diet and assigned to a 
replicated 5 × 5 Latin square design with 7-d experimental periods; the last 3 d of each 
experimental period was used for sample collection. The 7 d before administration of treatments 
was used as a covariate period with milk and blood samples being collected the last 3 d. 
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Replicate 1 was conducted in 2013 (from August 8 to September 19), and replicate 2 was 
conducted in 2014 (from June 5 to July 17). The experimental treatments were: 1) 0 g/d Met 
(negative control), 2) 12 g/d of abomasally infused DL-Met, 3) 24 g/d abomasally infused DL-
Met, 4) 15 g/d of fed DL-Met (20 g/d of Smartamine M), and 5) 30 g/d fed DL-Met (40 g/d of 
Smartamine M). The Met used for infusion was supplied by Adisseo. Treatment amounts of 
Smartamine M were based on a guaranteed minimum concentration of 75% Met and an assumed 
Met bioavailability of 80% (provided by Adisseo). The lot number for the Smartamine M used in 
the study was 1212357013.  It had a reported Met concentration of 77.40%, a protection rate of 
99.04%, and an intestinal digestibility of 95.26% (data provided by Adisseo). 
 The Met infusion solutions were prepared daily at 1300 h by mixing with 4 L of 50ºC 
tap water. Solutions were infused continuously into the abomasum (Gressley et al., 2006) via the 
ruminal cannula using a peristaltic pump (Masterflex; Cole-Parmer, Vernon Hills, IL). The pump 
was turned off and the infusion lines disconnected during milking times for approximately 45 
min/milking. Pumping rates (175 mL/h) were adjusted and monitored to ensure uniform and 
complete daily administration of Met. The RP-Met treatments were mixed with 1.0 kg of TMR, 
placed in rubber tubs, and fed 30 min before each of the 3 daily feedings. The TMR and RP-Met 
mixtures not consumed within 15 min were administered via the ruminal cannula. 
  
Management of Cows and Feed Collection and Analyses  
Cows were housed in a naturally ventilated tie-stall barn, fed individually and ad libitum 
with minimal orts (2 to 4%), and had continuous access to water. Cows were milked twice daily 
at 0430 and 1530 h with milk weights recorded at each milking. The basal diet (Table 12) was 
fed 3 times daily at 0500, 1300, and 2100 h using a Super Data Ranger mixer (American Calan 
 77 
 
Inc., Northwood, NH). Samples of TMR and orts were collected daily and composited by equal 
weight in each period for determination of DM. The NRC (2001) evaluation of the consumed 
basal ration is shown in Table 12. 
Samples of corn and haycrop silages were collected daily throughout the studies. Blood 
meal, supplemental fat, and vitamin and mineral mixes were collected weekly. The individual 
feedstuffs used to make the concentrate mix were sampled at the feed mill (Poulin Grain, 
Newport, VT) and sent to the University of New Hampshire Fairchild Dairy Teaching and 
Research Center. Ingredients were freeze-dried (Labconco Model 5, Kansas City, MO) for 48 h. 
Samples were then stored in air-tight glass jars until the completion of the study and ground to 
pass through a 1-mm screen using a Wiley mill (Thomas Scientific; Arthur H. Thomas, 
Philadelphia, PA).  
Composites of each ingredient were shipped to a commercial laboratory (Dairy One 
Cooperative Inc., Ithaca, NY) for nutritional analyses according to the following methods: DM 
(method 930.15; AOAC, 2006), CP (method 990.03; AOAC, 2006), NDF [Ankom Technology 
method 6 (NDF in feeds-filter bag technique for A200; Ankom Technology, Fairport, NY); 
solutions as in Van Soest et al., 1991], ADF [Ankom Technology method 5 (ADF in feeds-filter 
bag technique for A200; Ankom Technology); solutions as in method 973.18; AOAC, 1998], 
crude fat (method 2003.05; AOAC, 2006), and ash (method 942.05; AOAC, 2006). Feeds were 
also analyzed for AA concentration (cation-exchange chromatography coupled with post-column 
ninhydrin derivatization and quantitation method; method 982.30; AOAC, 2006; University of 
Missouri Experimental Station Chemical Laboratories, Columbia, MO). The chemical and AA 




Milk Sampling and Analyses  
Milk samples were collected at each milking during the last 3 d of each experimental 
period. Samples were preserved in tubes containing 2-bromo-2-nitropropan-1,3 diol, pooled by 
cow for each day according to daily milk weights, and refrigerated at 4°C until shipped to a 
commercial laboratory for determination of fat, true protein, lactose, and MUN by mid-infrared 
reflectance spectroscopy (Dairy One Cooperative, Inc.). 
 
Blood Sampling and Analyses   
Blood samples were collected at 2, 4, 6, and 8 h after the morning feeding during the last 
3 d of each experimental period. Blood was collected in 10-mL vacutainer tubes (Monoject, 
Mansfield, MA) containing 15% EDTA. Tubes were placed immediately on ice and centrifuged 
within 10 to 15 min at 1,200 × g for 20 min at 4°C. A 4-mL aliquot of plasma from each sample 
was placed in a glass test tube with 1.0 mL of 15% (wt/vol) 5-sulfosalicylic acid added to each 
tube. The tubes were allowed to sit for 10 min in the centrifuge before a second centrifugation 
(1,200 × g for 20 min at 5°C). An aliquot of 0.45 mL was removed, placed into labeled 1.8-mL 
cryovials for each cow, and stored at –80°C.  Deproteinized plasma samples were analyzed for 
AA at the University of Missouri Experimental Station Chemical Laboratories, Columbia, MO 
by cation-exchange chromatography coupled with post-column ninhydrin derivatization (indicate 
the method #, which would be different from that for feeds).  Norleucine was used as the internal 






The UNIVARIATE procedure of SAS (SAS version 9.4) was used to determine outliers. 
An observation greater than 2.0 SD from the mean for Met and TSAA (i.e., Met + Cys-Cys + 
Cystathionine/Allocystathionine + Homocystine + Tau) were considered an outlier and removed 
from the dataset. A similar outlier determination approach was used for the concentrations and 
yields of milk components. All production and plasma Met and TSAA data for one cow from 
replicate 2 were removed as a result of the outlier analysis. There were 8 additional plasma data 
points removed, as a result of disconnection of the infusion line or pump problems: 3 from a cow 
in replicate 1 receiving 24 g/d of infused Met and 5 from replicate 2 for the following treatments: 
15 g/d fed Met (n = 1), 30 g/d fed Met (n = 1), 12 g/d infused Met (n = 2), and 24 g/d infused 
Met (n = 1).   
Data for DMI, milk yield, concentrations and yields of milk components, and plasma 
concentrations of AA were analyzed using the REPEATED procedure of SAS (SAS version 9.4; 
Cary, NC) according to the following model: 
 Yijklm = μ + Li + Pj + Dk + Rl + LDik + βCijklm + Eijklm 
where  Yijklm = is the dependent variable, μ = overall mean, Li = is the fixed effect of the i
th
 level 
of Met, Pj = is the fixed effect of the j
th
 period, Dk = is the fixed effect of the k
th
 day, Rl = is the 
fixed effect of the l
th
 replicate, LDik = is the fixed effect of the interaction between the i
th
 level of 
Met and the k
th
 day, β = is the regression coefficient of the covariate C, Cijklm = is the value of the 
covariate variable for the m
th
 cow within the k
th
 day of the i
th
 level of Met, and Eijklm = is the 
random residual ~N (0, 2e ). The random effect of cow(replicate) was used as the error term for 
the effect of day and day × level interaction. Degrees of freedom were calculated using the 
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Kenward-Roger option of the MIXED procedure (SAS, 2010). Significance was noted at P ≤ 
0.05 and trends at P ≥ 0.05 to P ≤ 0.10. 
Day and day × level interaction were not significant, therefore the means for plasma AA 
concentration and milk parameters were calculated and analyzed using the PROC MIXED 
procedure of SAS according to the following model: 
Yijkl = μ + Li + Pj + Rk + βCijlm + Eijkl 
where  Yijlm = is the dependent variable, μ = overall mean, Li = is the fixed effect of the i
th
 level 
of Met, Pj =is the fixed effect of the j
th
 period, Rk = is the fixed effect of the k
th
 replicate, β = is 
the regression coefficient of the covariate C, Cijlm = is the value of the covariate variable for the 
l
th
 cow within the i
th
 level of Met, and Eijlm = is the random residual ~N (0,
2
e ). The random 
effect of cow(replicate) was used as the error term. Degrees of freedom were calculated using the 
Kenward-Roger option of the MIXED procedure of SAS. Significance was noted at P ≤ 0.05 and 
trends at P ≥ 0.05 to P ≤ 0.10. Linear and quadratic effects were determined using the 
CONTRAST statement of SAS. The PDIFF option of SAS was used to separate least square 
means. 
The least square means for plasma AA were calculated for: 1) all AA, total EAA, total 
NEAA, total AA, total branched chain AA, total urea cycle AA, total sulfur AA, total AA minus 
total sulfur AA, expressed on micromolar basis, 2) Met as percentage of total AA  minus Met, 3) 
TSAA as a percentage of total AA minus TSAA. Plasma concentrations of total AA were 
determined by the sum of: Arg, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Val, Ala, Asn, Asp, Cit, 
Cys, cystathionine/allocystathionine, Gln, Glu, Gly, homocysteine, Orn, Pro, Ser, Tau, and Tyr. 
The AA considered in calculation of total EAA, total NEAA, total AA, total branched chain AA, 
total urea cycle AA, and total sulfur AA are presented as footnotes to Table 15. Least square 
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means for Met and Met as a percentage of total AA minus Met, and total SAA and total SAA as 
a percentage of total AA minus total SAA were subjected to the REG procedure of SAS to 
generate the regression coefficients, slopes, and r
2
 using the slope ratio assay (Finney, 1978).  
The Met bioavailability values were determined using the following equation:   
Bioavailability = [(slope of the RP-Met treatment ÷ slope of the infusion treatment) x 
100] 
RESULTS 
Production and intake data are presented in Table 14. There were no significant effects of 
treatments on DMI, yields of milk yield, 4% FCM, and ECM, as well as concentration and yield 
of milk fat, yields of milk true protein and lactose, concentration of MUN, and feed efficiency.  
These results were expected because of the short experimental periods. However, the milk 
concentration of true protein increased for both infused Met (P = 0.002) and fed RP-Met (P = 
0.0003), whereas that of milk lactose decreased (P = 0.001) for infused Met only.  
Plasma AA concentrations are reported in Table 15. There were no significant effects of 
treatments on the plasma concentration of Trp, Asp, Cit, Glu, homocysteine, and Pro. However, 
there were significant linear increases in plasma concentrations of Met, Cys, 
cystathionine/allocystathionine, and Tau with both Met infusion and RP-Met treatments. In 
contrast, there were significant linear decreases for His, Ile, Leu, Thr, Asn, Gln, Gly, Ser, and 
Tyr with the infusion treatments but not the RP-Met treatments.  Also, there were trends for 
linear decreases in the plasma concentrations of Val and Ala, and significant quadratic responses 
for Arg, Lys, and Orn with the infusion treatments but not with the RP-Met treatments, and. 
Trends for linear decreases in the plasma concentrations of Ser and Tyr were observed for cows 
fed RP-Met.  
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The plasma concentrations of total EAA, total NEAA, total AA, total branched-chain 
AA, total urea-cycle AA, TSAA, and total AA minus total TSAA are reported in Table 16. There 
were no significant treatment effects on plasma concentrations for total EAA and total urea-cycle 
AA. Plasma concentrations of TSAA increased linearly with both infusion and RP-Met 
treatments. Significant linear decreases occurred for plasma concentrations of total NEAA, total 
AA, total branched-chain AA, and total AA minus total TSAA for the infusion treatments, 
whereas no effects were observed for these variables with the RP-Met treatments.. 
Met bioavailability values and the relevant statistical data (slope, SE and CV) for the 
infusion and RP-Met treatments using the 4 different plasma response variables (Met 
concentrations, Met as a percentage of TAA concentrations, TSAA concentrations, and TSAA as 
a percentage of TAA concentrations) are presented in Table 17. The corresponding dose-
response plots, associated equations and relevant statistical data for the plots (SE of slope, SE of 
intercept, R
2
, and RMSE values) are presented in Figures 16-19, respectively. The calculated 
Met bioavailability values (and associated 95% confidence intervals) for Smartamine M based on 
the plasma response variables of Met, Met as a percentage of TAA, TSAA, and TSAA as a 
percentage of TAA were 74.4 (72.1 – 76.7), 73.6 (72.4 – 74.8), 81.8 (78.8 – 84.8), and 80.9 (80.5 
– 81.3), respectively (Table 17).  
DISCUSSION 
 The first object of this experiment was to confirm linearity in plasma Met response over a 
range of absorbed amounts of Met that varied between a predicted moderate deficiency of Met to 
a modest oversupply relative to Lys, the expected next limiting AA (NRC, 2001).  The NRC 
(2001) evaluation of the consumed basal diet indicated predicted concentrations of Lys and Met 
in MP of 6.41 and 1.68, respectively, confirming the desired low Met value and a wider Lys/Met 
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ratio than the optimum ratio of 3.0/1 required for maximum content and yield of milk protein. It 
appears that the basal diet was Met-deficient because of the observed increases in milk protein 
concentrations with the two Met infusion treatments and the two RP-Met treatments. Milk 
protein concentrations increased in incremental fashion to the 3 amounts of infused Met (2.83, 
2.89 and 2.94%, respectively) but in a quadratic fashion to the 3 amounts of dietary Smartamine 
M (2.83, 2.95 and 2.95%, respectively). It is less certain if a modest oversupply of Met occurred 
with the highest amounts of supplemental Met.  However, the combined results from the two 
sources of supplemental Met would indicate that at least some oversupply of Met was achieved 
as the intermediate amount of dietary Smartamine M  was adequate to support the maximal milk 
protein concentration of 2.95%.  As expected, because of the extremely short experimental 
periods, there were no significant effects of treatments on yields of milk or milk true protein. 
The increase in milk protein concentrations with increasing Met either infused or fed has 
been shown by other researchers, while increases in milk protein yields varies (Zanton et al., 
2014; Patton,2010) . For instance, Pisulewski et al. (1996) and Socha et al. (2008) duodenally 
infused incremental amounts of Met and reported increases in milk protein concentrations. 
Rulquin and Delaby (1997) fed Smartamine M and observed an increase in milk protein 
concentrations. Pisulewski et al. (1996), Rulquin and Delaby (1997), and Socha et al. (2008) also 
showed increases in milk protein yield, which was not observed in the present study. Guinard 
and Rulquin (1995) reported a linear increase in milk protein concentration while infusing 
incremental amounts of Met, but no effect on milk protein yield, which is similar to what we 
observed. 
Bioavailability for Smartamine M has been determined using methods such as 
measurements of apparent rumen protection and intestinal absorption of Met using lactating 
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dairy cows fitted with rumen and duodenal cannulae (Robert and Williams, 1997a), the AUC 
technique (Robert and Williams, 1997b; Graulet et al., 2005; Devillard et al., 2011), the mobile 
bag technique (Overton et al., 1996; Berthiaume et al., 2000; Koenig and Rode, 2001;) ), and the 
plasma free AA dose response method (Rulquin and Kowalczyk, 2003). Robert and Williams 
(1997a) reported an average bioavailability of 80% but values ranged from non-statistical 
differences of 75 to 97%. Their approach consisted of feeding a fixed amount of Smartamine M 
(39.6 g/d of supplementary Met) to cows fed differing proportions of grass and corn silage and 
measuring duodenal flows and fecal excretions of Met. While their results indicated excellent 
resistance of the product to rumen degradation and excellent intestinal release of Met, the results 
also supported the notion that the technique lacked the precision needed for establishing Met 
bioavailability values for RPMet supplements. Large ranges in bioavailability values have also 
been reported by others who have made independent measurements of ruminal loss and intestinal 
loss of Met from dacron bags using the mobile bag technique for Mepron. For example, Overton 
et al. (1996) reported ruminal disappearances of 5.8 to 87.5% when samples were incubated from 
3 up to 96 h in the rumen, so the ruminal escape and intestinal disappearance ranged from 94.2 to 
12.5% and from 63.4 to 8.8%, respectively. Multiplying the ruminal escape by the intestinal 
disappearance values resulted in bioavailability ranging from 59.7 to 1.1% when using 3 or 96 h 
of incubation in the rumen, respectively. Koenig and Rode (2001) also reported large ranges of 
bioavailability values depending on which ruminal incubation time was used. Their ruminal 
escape and intestinal disappearance ranged from 91.4 to 14.5% and from 35.9 to 4%, 
respectively, as 3 or 96 h was used for incubation in the rumen. The calculated bioavailabilities 
ranged from 32.8 to 0.58%, respectively. These are large ranges for bioavailabilities compared to 
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the values we observed using the plasma free AA dose response method where the confidence 
intervals for the bioavailabilities were ≤ 3.0. 
The mobile bag technique to determine intestinal disappearance has inherent limitations 
and errors resulting in over- or underestimation of bioavailability values of RP-AA supplements 
tested. The first limitation is that the effects of eating and rumination are not considered. Second, 
flow out of the rumen for the RPAA is important because this can lead to over- or 
underestimation of how much product is actually escaping the rumen. This can be seen with the 
results of Overton et al. (1996), Berthiaume et al. (2000), and Koenig and Rode (2001) where the 
researchers incubated the bags in the rumen for different periods of time and as already stated, as 
incubation time increased above 12 h an increasing amount of AA was released from the RPAA 
supplement as compared to the 3 and 6 h incubation times. Therefore, if the retention of the 
RPAA is greater than 12 h in the rumen, less of the RPAA makes it to the small intestine and this 
would impact bioavailability values.  
An inherent error with the mobile bag technique is the assumption that AA disappearance 
from bags incubated in the rumen or duodenum equates to degradation or digestibility, which 
may or may not be true. Reynal et al. (2007) observed that 10% of the total AA flow out of the 
rumen are soluble AA of dietary origin and that this indicated an escape of soluble N from 
ruminal degradation. Therefore, if a portion of the RPAA are solubilized and leave the bag while 
incubated in the rumen they may escape ruminal degradation and flow onto the small intestine. 
Berthiaume et al. (2000) also stated that the physical barrier created by the bags may contribute 
to decreased disappearance in the small intestine because it restricts the contact between the 
RPAA and the intestinal digesta. The plasma free AA dose response method eliminates these 
concerns because no bags are used and the RPAA has direct contact with the digesta at all times. 
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 Graulet et al. (2005) and Devillard et al. (2011) used the plasma AUC to determine the 
Met bioavailability of Smartamine M.  They reported values of 74 and 81%, respectively. Even 
though these values are similar to those reported in the present study, both Graulet et al. (2005) 
and Devillard et al. (2011) used dry dairy cows, whereas lactating animals were used herein. 
Concerns with the plasma AUC method are that the animals receive a large pulse dose of either 
RPAA or infusion, which is not normally encountered in typical feeding conditions. Another 
concern is that the RPAA is neither consumed by the animal nor exposed to the TMR. The pulse 
dose is deposited directly through the cannula into the rumen at the level of the liquid phase just 
under the fibrous material (Graulet et al., 2005), so it may have flowed out of the rumen faster 
than if it was fed.  Finally, it has been observed that estimates of bioavailability for both Met 
(Graulet et al., 2005) and Lys (Evans et al., 2013) are linearly related to the amount of the pulse 
dose; so the greater the dose, the greater the bioavailability.  
Rulquin and Kowalczyk (2003) were the first researchers to suggest using a plasma free 
AA dose response method to determine bioavailability of AA in RPAA. They reported a 
bioavailability value of 75 ± 11% for Met. In their study, the calibration phase consisted of 
infusing graded amounts of Met into the duodenum, which was not done concomitantly with 
feeding of graded amounts of Smartamine M. (Note: I don’t understand this it was done 7 d 
before and 7 d after the Smartamine M portion of the trial.) In the present study, the 
bioavailability obtained with RP-Met averaged 74.4 ± 2.3% when plasma concentration of Met 
was expressed on a micromolar basis and 73.6 ± 1.2% when Met was expressed as a percentage 
of total AA (minus Met).. These bioavailability values are very similar to the value reported by 
Rulquin and Kowalczyk (2003) except that our confidence intervals were much smaller. This 
may be explained by the use of more cows than used by Rulquin and Kowalczyk (2003) (9 vs. 
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3), thus resulting in less animal variability. We also run the infusion of Met, which was 
equivalent to the calibration phase in Rulquin and Kowalczyk (2003) study, concomitantly with 
feeding RP-Met and this may have reduced variability as well. Even though there was not a large 
difference between the bioavailability of Met reported on a micromolar basis or as percentage of 
total AA, the confidence interval and coefficient of variation for both infusion and fed RP-Met 
were smaller when expressing Met as a percentage of total AA.  
It is important to note, however, that Met is involved as a precursor to the synthesis of 
other sulfur-containing AA and metabolites, thus suggesting that TSAA concentration should be 
the best choice of plasma metabolites to determine RP-Met bioavailability. In the present study, 
all the sulfur AA analyzed except homocysteine increased linearly with increasing supplies of 
Met. Increases in total sulfur AA as a result of Met supplementation have been also been 
reported by others (Guinard and Rulquin, 1995; Pisulewski et al., 1996; Varvikko et al., 1999). 
The lack of effect of Met supplementation on homocysteine observed herein is not surprising as 
homocysteine is converted back to Met or to Cys. The difference between the bioavailability of 
the RP-Met expressed as plasma concentration of TSAA on a micromolar basis (81.8 ± 3.0%) or 
as a percentage of total AA concentration (80.9 ± 0.4%) was relatively small. The confidence 
intervals for the bioavailabilities and the coefficient of variation for the slopes for both infusion 
and Smartamine M are smaller for the TSAA as a percentage of total AA concentration versus 
the TSAA on a micromolar, therefore suggesting the most accurate value to use is the TSAA as a 






It is concluded that there is linearity in response of plasma Met and total sulfur AA 
concentrations to increasing amounts of absorbed Met and that using total sulfur AA rather than 
Met in calculating bioavailability values is the best approach. Due to the lower confidence 
intervals and coefficients of variation, expressing TSAA as a percentage of total AA 
concentration appears the most accurate. It is also concluded, from a comparison of our results 
with those of others using different techniques, that the plasma free AA dose-response approach 
is a preferred method for obtaining animal derived estimates of bioavailability of Met in RP-Met 
products. However, we do encourage others that use the technique to seek ways to improve its 
precision. 
There are difficulties associated with the plasma free AA dose response method. First is 
the assumption that the AA infused into the abomasum is absorbed at the same rate as the AA 
from the fed RPAA. Second is making sure that within a 24 h period all the infusion is 
distributed at a continuous rate. Third is feeding the RPAA 3 times a day supplying the small 
intestine with a continuous supple of AA like the infusion is. Even with these assumptions and 
challenges using the plasma free AA dose response method should be the standardized methods 
used to determine bioavailabilities for rumen protected methionine supplements. This method is 
animal based like the in situ and AUC, but lacks the problems associated with the in situ, such 
AA disappearance from the in situ bags incubated in the rumen or duodenum would equal to 







Table 12. Ingredient and chemical composition of the basal diet infused with Met or 
supplemented with rumen-protected Met 
Ingredient            % of DM 
Corn silage, mature 34.0 
Mixed mostly grass silage, mid-maturity 14.5 
Steam flaked corn 4.56 
Citrus pulp 8.68 
Corn meal 11.9 
Soy hulls 3.64 
Distillers grains 1.08 
Soybean meal 10.1 
Canola meal 3.20 
ProvAAL-Lysine
2






Mineral/vitamin mix 3.24 








NEL balance, Mcal/kg 1.64 
RDP balance, g/d 10.0 
RUP balance, g/d -116 
MP-Lys, % MP 6.41 
MP-Met, % MP 1.68 
MP-Lys, g/d 174 
MP-Met, g/d 46 
1
AG Processing Inc. 
2
Berg + Schmidt America LLC, Libertyville, IL. 
3
NRC evaluation of the control diets using post study means





Table 13. Chemical and AA composition of feedstuffs (% of DM unless otherwise noted) fed to Holstein cows infused with Met or 






























DM 30.0 35.6 90.8 93.6 92.1 91.6 92.0 92.3 93.0 95.6 75.3 99.7 98.9 
CP 8.1 15.6 7.7 42.1 7.6 8.2 52.4 28.8 11.0 89.6 6.60 288 - 
NDF 43.8 61.2 10.2 30.9 23.4 10.9 10.7 37.1 68.8 - - - - 
ADF 27.2 41.0 3.20 22.4 20.2 3.50 8.30 16.6 48.9 - - - - 
NDFCP 1.80 4.60 1.20 7.80 3.00 1.90 4.90 7.30 4.30 - - - - 
ADFCP 0.70 1.50 0.50 3.40 2.00 1.00 2.70 2.90 1.60 - - - - 
Lignin 3.10 6.20 0.90 10.9 1.90 1.00 0.80 3.60 2.00 - - - - 
NFC 40.5 13.7 77.4 24.1 61.2 76.8 32.8 21.0 17.9 - - - - 
Starch 29.3 0.70 69.6 0.80 0.60 68.1 2.00 1.10 0.30 - - - - 
Ether extract 4.00 4.60 4.00 3.30 3.10 4.20 1.50 14.8 1.90 3.20 3.80 - - 
Ash 5.50 9.40 1.90 7.50 8.00 1.80 7.50 5.60 4.70 7.70 15.5 - - 
Ca 0.20 0.60 0.00 0.70 2.10 0.00 0.30 0.00 0.60 1.60 1.00 - 12.7 
P 0.30 0.40 0.30 1.20 0.10 0.30 0.70 0.90 0.10 0.30 0.10 - 1.60 
Mg 0.10 0.30 0.10 0.60 0.20 0.10 0.30 0.30 0.20 0.10 0.30 - 4.60 
K 1.30 2.80 0.40 1.40 1.00 0.40 2.40 1.30 1.40 0.40 5.50 - 0.10 
Na 0.00 0.10 0.00 0.10 0.10 0.00 0.00 0.10 0.00 0.40 0.10 - 14.3 
Cl 0.20 0.50 0.10 0.40 0.20 0.10 0.10 0.10 0.10 - - - 8.6 
Fe, ppm 925 358 33.0 169 78.5 24.5 120 101 451 2,200 178 - 4,085 
Zn, ppm 22.5 29.0 22.0 61.0 13.5 24.5 52.0 60.5 54.0 47.0 9.50 - 611 
Cu, ppm 5.00 9.50 2.00 6.00 8.00 2.00 16.0 7.00 7.50 4.50 6.50 - 346 
Mn, ppm 11.5 58.5 5.00 67.0 11.5 5.00 31.0 12.5 14.0 8.00 11.0 - 1,003 
S 0.10 0.30 0.10 0.80 0.10 0.10 0.40 0.50 0.10 0.90 0.90 - 0.50 
Arg, %CP 1.56 2.02 4.56 5.71 3.62 4.22 7.01 4.58 4.34 4.47 0.09 - - 
His,%CP 1.02 1.10 2.76 2.54 1.60 2.73 2.52 2.70 2.43 4.89 0.21 - - 





Ile, %CP 3.45 3.37 3.46 3.87 3.12 3.37 4.48 4.02 3.72 1.67 0.90 - - 
Leu, % CP 8.25 5.75 11.1 6.89 5.66 11.1 7.53 12.4 6.34 11.5 0.90 - - 
Lys, % CP 2.57 3.02 3.60 5.29 2.61 3.20 6.17 3.15 6.30 6.65 0.39 - - 
Met, % CP 1.49 1.21 2.02 1.93 0.94 1.94 1.34 1.93 1.00 0.91 0.09 - - 
Phe, % CP 3.25 3.48 4.62 3.86 3.63 4.52 4.88 5.12 3.48 6.18 0.60 - - 
Thr, % CP 2.78 2.91 3.58 4.16 3.12 3.56 3.75 4.11 3.44 3.85 0.93 - - 
Trp, % CP 0.54 0.57 0.76 1.17 1.16 0.90 1.46 0.72 0.57 1.32 0.83 - - 
Val, % CP 4.39 4.11 4.61 4.87 3.84 4.38 4.49 5.15 4.14 7.87 1.43 - - 
1




Table 14. Milk yields, milk composition, DMI and milk/DMI for Holstein cows fed a Met 
deficient diet supplemented with increasing amounts of Met, either infused or fed as Smartamine 
M. 











Item 0 12 24 15 30 Inf. Smart Inf. Smart 
Milk yield, kg/d 46.8 46.1 45.4 45.8 46.3 1.03 0.68 0.28 0.53 
DMI, kg/d 23.4 23.2 22.8 23.3 23.8 0.33 0.50 0.35 0.62 
Milk fat, % 3.60 3.52 3.64 3.67 3.50 0.07 0.09 0.67 0.56 
Milk fat, kg/d 1.67 1.62 1.68 1.68 1.62 46.1 51.7 0.96 0.49 










 0.03 0.02 <0.001 <0.001 
Milk true protein, kg/d 1.32 1.33 1.33 1.35 1.37 34.4 22.1 0.69 0.27 










 0.04 0.04 0.01 0.57 
Milk lactose, g/d 2.25 2.21 2.15 2.20 2.21 58.0 35.2 0.14 0.41 
MUN, mg/dL 14.0 13.9 13.6 12.9 13.7 0.62 0.60 0.64 0.76 
4% FCM, kg/d
1 
47.4 46.2 46.7 47.1 46.3 1.20 1.03 0.69 0.45 
ECM, kg/d
2 
46.6 45.7 46.2 46.7 46.1 1.18 0.91 0.85 0.67 
Milk yield/DMI 2.02 2.01 2.00 2.00 1.98 0.05 0.06 0.80 0.66 
a,b,c
 Means in the same row differ (P<0.02) 
1
 4% FCM = (0.4255 × milk yield, kg) + (16.425 × (milk yield, kg × fat, %)) 
2




Table 15. Plasma amino acids concentration (µM) in Holstein cows fed a Met deficient diet 
supplemented with increasing amounts of Met, either infused or fed as Smartamine M. 
 Methionine levels, g/d   










- 2.70 0.03 (Q) 








- 1.73 0.04 








- 2.85 0.03 








 4.84 0.05 








- 2.61 0.02(Q) 








- 2.64 <0.001 














- 1.05 0.05 








- 4.31 0.03 
 Smartamine M 117 - 112 - 113 4.39 0.46 
Trp 
 Infusion 48.3 48.1 - 45.7 - 2.09 0.37 
 Smartamine M 48.3 - 45.9 - 48.4 1.89 0.95 
Val 
 Infusion 289 278 - 269 - 9.16 0.06 
 Smartamine M 289 - 275 - 271 10.2 0.21 
Ala 
 Infusion 291 290 - 265 - 9.86 0.07 








- 1.62 0.03 
 Smartamine M 56.9 - 55.9 - 55.3 2.00 0.50 
Asp 
 Infusion 4.98 4.67 - 3.77 - 0.76 0.21 
 Smartamine M 4.98 - 4.41 - 4.70 0.71 0.91 
Cit 
 Infusion 100 98.6 - 95.8 - 3.65 0.38 










- 0.71 <0.01 














- 0.13 <0.001 














- 5.26 <0.001 
 Smartamine M 215 - 207 - 202 8.01 0.17 
Glu 
 Infusion 37.2 36.2 - 35.9 - 2.31 0.62 








- 11.7 0.01 
 Smartamine M 341 - 329 - 316 12.4 0.16 
Homocystine 
 Infusion 1.17 1.22 - 1.20 - 0.05 0.66 








- 2.04 0.05 (Q) 
 Smartamine M 47.0 - 47.8 - 49.5 1.95 0.21 
Pro 
 Infusion 92.0 92.2 - 86.3 - 2.49 0.13 








- 3.13 <0.01 














- 1.82 <0.01 














- 1.61 <0.001 








 Means in the same row differ (P<0.02).   
1





Table 16. Plasma amino acids (µM) in Holstein cows fed a Met deficient diet supplemented with 
increasing amounts of Met, either infused or fed as Smartamine M. Cont 
 Methionine levels, g/d  Linear 
Item 0 12 15 24 30 SEM P-value 
Total EAA 
 Infusion 1,032 1,042 - 1,002 - 28.2 0.31 








- 32.3 0.02 
 Smartamine M 1,406 - 1,373 - 1,358 39.4 0.37 







- 54.4 0.04 
 Smartamine M 2,441 - 2,384 - 2,383 66.8 0.56 







- 16.6 0.05 
 Smartamine M 568 - 540 - 532 20.0 0.20 
Total urea cycle AA 
 Infusion 234 240 - 226 - 7.00 0.36 
 Smartamine M 234 - 232 - 239 7.60 0.49 







- 3.30 <0.001 














- 52.3 <0.01 
 Smartamine M 2,352 - 2,266 - 2,243 64.3 0.23 
a,b,c








Table 17. Bioavailability calculations using changes in plasma free Met or TSAA. 
 Infusion  Smartamine M   
Item slope SE CV  slope SE CV Bioavailability 95% CI 
Met, µM 1.39777 0.0459 2.57  1.03988 0.0180 1.53 74.4 72.1 – 76.7 
Met, %TAA 0.06635 0.0027 0.97  0.04883 0.0016 1.22 73.6 72.4 – 74.8 
TSAA, µM 2.00321 0.0608 1.81  1.63864 0.0816 1.69 81.8 78.8 – 84.8 







Figure 16. Response of plasma Met concentrations (µM) to graded levels of infused DL-Met (♦) 
and fed Smartamine
®M (■) in lactating dairy cows fed a Met deficient diet. There was a linear 
effect on Met plasma concentration for Met infusion [Y = 19.1 + 1.40x; P < 0.001, SE slope = 
0.046, SE intercept = 1.83, R
2
 = 0.99, RMSE = 1.35] and Smartamine M [Y = 19.1 +1.04x; P < 
0.001, SE slope = 0.018, SE intercept = 1.23, R
2







Figure 17. Response of plasma Met concentrations (%TAA) to graded levels of infused DL-Met 
(♦) and fed Smartamine®M (■) in lactating dairy cows fed a Met deficient diet. There was a 
linear effect on Met plasma concentration for Met infusion [Y = 0.84 +0.066x; P < 0.001, SE 
slope = 0.003, SE intercept = 0.10, R
2
 = 0.99, RMSE = 0.08] and Smartamine M [Y = 0.84 
+0.049x; P < 0.001, SE slope = 0.001, SE intercept = 0.06, R
2






Figure 18. Response of plasma TSAA concentrations (µM) to graded levels of infused DL-Met 
(♦) and fed Smartamine®M (■) in lactating dairy cows fed a Met deficient diet. There was a 
linear effect on TSAA plasma concentration for TSAA infusion [Y = 89.5 + 2.00x; P < 0.0001, 
SE slope = 0.061, SE intercept = 2.58, R
2
 = 0.99, RMSE = 1.79] and Smartamine M [Y = 89.5 
+1.64x; P < 0.001, SE slope = 0.082, SE intercept = 2.66, R
2






Figure 19. Response of plasma TSAA concentrations (%TAA) to graded levels of infused DL-
Met (♦) and fed Smartamine®M (■) in lactating dairy cows fed a Met deficient diet. There was a 
linear effect on TSAA plasma concentration for TSAA infusion [Y = 3.71 + 0.104x; P < 0.001, 
SE slope = 0.005, SE intercept = 0.10, R
2
 = 0.99, RMSE = 0.14] and Smartamine M [Y = 3.71 
+0.084x; P < 0.001, SE slope = 0.004, SE intercept = 0.10, R
2







Optimal blood sampling times to determine bioavailability of rumen-protected methionine 
products using the plasma free amino acid dose-response method 
 
INTRODUCTION 
The plasma free AA dose-response method has been used to determine the bioavailability 
of rumen protected (RP) Lys (RP-Lys) and Met (RP-Met) supplements (Whitehouse et al. 2012, 
2014; Chirgwin et al., 2015). Cows are fed at 8 h intervals and receive graded amounts of Met 
via abomasal infusion or by feeding a RP-Met supplement. Latin square experiments with 7-d 
periods are used with all cows receiving all treatments. The approach for sampling blood has 
been to collect blood 2, 4, 6, and 8 h after the morning feeding on the last 3 d of each a 7-d 
experimental period. The deproteinized plasma samples from the 4 sampling times are pooled for 
each cow for each day, resulting in 3 plasma samples per cow for AA analyses for each sampling 
period. The objective of this experiment was to determine if the outlined blood sampling 
schedule captures the 24-h variation in plasma Met concentrations and yields unbiased estimates 
of Met bioavailability. We hypothesized that plasma Met concentrations determined as described 
above would not be affected by sampling time of blood collections. 
MATERIALS AND METHODS 
All procedures related to animal care were conducted with approval of the University of 
New Hampshire Institutional Animal Care and Use Committee (IACUC no. 140403). The 
experiment was conducted at the University of New Hampshire Fairchild Dairy Teaching and 




Experimental Design and Treatments 
Five ruminally-cannulated Holstein cows averaging (mean ± SD) 148 ± 59 DIM, 53.8 ± 
8.9 kg/d of milk, and 709 ± 88 kg of BW at the beginning of the study and fed a Met-deficient 
basal diet were assigned to a 5 × 5 Latin square with 7-d experimental periods. The experimental 
treatments (per 25.0 kg/d of DMI) were: 1) 0 g/d Met (CON), 2) 12 g/d of abomasally infused 
Met (INF-12), 3) 24 g/d abomasally infused Met (INF-24), 4) 15 g/d of supplemental Met (20 
g/d of Smartamine M; RPM-15), 5) 30 g/d of supplemental Met (40 g/d of Smartamine M; 
RPM-30). 
The infusion solutions were prepared daily at 1300 h by mixing 4 L of tap water with 
DL-Met (Adisseo France SAS, Antony, France). The solution was infused continuously into the 
abomasum (Gressley et al., 2006) via the ruminal cannula using a peristaltic pump (Masterflex; 
Cole-Parmer, Vernon Hills, IL). The pump was turned off twice daily and the infusion lines 
disconnected for approximately 45 min each time to allow for morning and afternoon milking. 
Pumping rates (175 mL/h) were adjusted and monitored to ensure uniform and complete daily 
administration of Met. The RP-Met supplements were mixed with 1.0 kg of TMR, placed in 
rubber tubs, and fed 30 min before each of the 3 daily feedings. Total mixed ration plus RP-Met 
supplements not consumed within 15 min was administered via the ruminal cannula.  
Management of Cows  
Cows were housed in a naturally ventilated tie-stall barn, fed individually and ad libitum 
with minimal orts (2 to 4%), and had access to water throughout the duration of the experiment. 
Cows were milked twice daily at 0430 and 1530 h with milk weights recorded at each milking. 
The basal diet was fed 3 times daily at 0500, 1300, and 2100 h using a Super Data Ranger mixer 
(American Calan Inc., Northwood, NH). The basal diet contained (DM basis): 34.0% corn silage, 
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14.5% mixed mostly grass silage, 4.6% steam flaked corn, 8.7% citrus pulp, 11.9% corn meal, 
3.6% soybean hulls, 1.3% sugarcane molasses, 1.1% corn distillers grains with solubles, 10.1% 
soybean meal (48% CP), 3.2% canola meal, 0.2% urea, 2.2% ProvALL lysine
 
(Perdue 
AgriBusiness, Salisbury, MD), 1.4% Berga fat (Berg + Schmidt America LLC, Libertyville, IL), 
and 3.2% minerals and vitamins. Samples of TMR and orts were collected daily and composited 
by equal weight in each period for determination of DM.  
Blood Sampling and Analysis 
Jugular veins were catheterized with indwelling catheters. Catheters were made by 
placing a 20 G needle that had the tip ground off into 5 inches of micro medical tubing (0.76 I.D. 
x 0.048 O.D., Scientific Commodities, Inc., Lake Havasu City, AZ) and attaching  a 7 inch 
MicroCLAVE smallbone T-connector (Abbott Laboratoried, San Clemente, CA). Catheters were 
placed in the jugular veins on d 5 at 0900 h so that blood samples could be collected every 2 h 
over a 24 h period on d 5, 6, and 7 of each experimental period. This resulted in 12 blood 
samples per cow daily. Blood was collected using a 10-mL syringe and then placing into a 10-
mL vacutainer tube (Monoject, Mansfield, MA) containing 15% EDTAvol/vol. Tubes were 
placed immediately in a Chameleon Cooler (Fisher Scientific, Pittsburgh, PA) and centrifuged 
within 15 min of sample collection at 1,200 × g for 20 min at 5°C. A 1.0-mL aliquot was placed 
into1.8-mL cryovials and stored at –80°C for AA analyses. Plasma Met analysis was conducted 
using gas chromatography after chloroformate derivatization (EZ:faast™, Phenomenex) at the 
U.S. Dairy Forage Research Center (Madison, WI). 
Statistical Analysis 
The UNIVARIATE Procedure of SAS (version 9.4; SAS Cary, NC) was used to 
determine outlier values for plasma Met(µM). An observation greater than 2.0 SD from the mean 
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was considered an outlier. Due to catheter malfunctions, there were 702 samples collected of the 
900 originally intended. There were 25 outlier detected, which were removed from the dataset. 
The PROC MIXED procedure of SAS was used to determine the LSM for Met levels 
according to the following model: 
Yijkl = μ + Li + Pj + Hk + Dl + HDkl + LHDikl + Eijkl 
where  Yijkl = is the dependent variable, μ = overall mean, Li = is the fixed effect of the i
th
 level, 
Pj = is the fixed effect of the j
th
 period, Hk = is the fixed effect of the k
th
 hour, Dl = is the fixed 
effect of the l
th
 day, HDkl = is the fixed effect of the interaction between the k
th
 hour and the l
th
 
day, LHDikl = is the fixed effect of the interaction between the l
th
 level, the k
th
 hour, and the l
th
 
day, and Eijkl = is the random residual error ~N (0,
2
e ). In this model, the random effect of cow 
was used as the error term. Degrees of freedom were calculated using the Kenward-Roger option 
of the MIXED procedure of SAS. Significant Met level effects were noted at P ≤ 0.05. Linear 
and quadratic effects were determined using the CONTRAST statement of SAS. 
Using the slope ratio assay (Finney, 1978), the LSM from the MIXED procedure of SAS 
were subjected to the SAS REG procedure to generate the linear regression lines and slopes. The 
bioavailability of RPM was determined using the following equation: 
 Bioavailability = [slope of the RPM treatments ÷ slope of the INF treatments]. 
 
RESULTS AND DISCUSSION 
Lobos et al. (2015) compared the results of how the AA analysis performed by GC-CF 
using EZ:faast, with AA analysis by HPLC using IEC-ninhydrin from composited daily samples 
collected during the morning sampling period. The authors stated that the overall correlation 
between the two methods was 0.95 (P < 0.001), but that it varied for individual AAs. The 
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correlation for Met was 0.97. Therefore, the authors concluded that the method used to determine 
Met concentrations in this study was a valid method. 
There was no effect (P ≥ 0.36) of sampling day on plasma Met concentration for INF, 
CON, or RPM treatments (Table 18). These results strongly suggest that a 4 d adaptation period 
is adequate time for high producing lactating cows to establish steady state conditions for plasma 
Met concentrations when the outlined protocol is followed. This observation agrees with 
Benefield et al. (2009) who used 7- and 14-d period lengths and concluded that in Latin square 
studies in which RPAA were fed 7-d long experimental periods are acceptable. Although there 
was no effect of day on plasma Met concentrations, it is advised that blood samples be collected 
for a minimum of 3 consecutive days to allow for capturing normal variation, detection of outlier 
values, and improved accuracy of results. The high SEM (5.08 µM) for the INF-24 treatment 
(Table 18) was numerically greater than for the RPM-30 treatment, because data from 1 cow for 
d 2 and 3 of period 2 were not collected due to catheter malfunction. 
 There was also no effect (P ≥ 0.51) of sampling time (hour) on plasma Met concentration 
for INF or RPM treatments (Table 19). The mean Met concentration for the 2-8 h sampling 
period did not differ from the 10-16 or the 18-24 h periods, and the 10-16 sampling period did 
not differ from the 18-24 h sampling period. Lapierre et al (2012) observed that taking blood 
samples on 1 day and pooling the samples can result in increased variation especially when 
measuring arterio-venous differences. The authors presented a theoretical example for arterio-
venous differences where two scenarios were presented where blood samples were pooled 
compared to individual arterial and venous samples. The CV for the individual samples was 33 
vs. 16%, but the pooled samples might range from 23 to 63 or 37 to 56 µM which is considerably 
larger variation. In this study, samples were not pooled, but analyzed individually. After 
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statically analysis was done that demonstrated no difference for day, the three individual day 
samples were then averaged together. Therefore, the routine method of sampling blood every 2 h 
after the morning feeding (2-8 h time period) for plasma Met analysis appeared to have 
adequately captured diurnal variation associated with feeding patterns and changes in metabolic 
activity.  
 For all days and collection time points, plasma Met concentrations averaged 18.3, 28.2, 
48.4, 35.9, and 53.8 µM for CON, INF-12, INF-24, RPM-15, and RPM-30, respectively (data not 
shown). Methionine bioavailability estimates for RPM averaged 84.7, 84.4, 90.0, and 84.6% for 
blood samples collected from 2-8, 10-16, 18-24 h, and 2-24 h, respectively (Table 20). These 
bioavailabilities are in agreement with other bioavailability estimates on the same source of RPM 
(Rulquin and Kowalczk, 2003; Chirgwin et al., 2015). The similarity in estimates of 
bioavailability for SM for the 2-8 and 2-24 h sampling periods indicates that the blood sampling 
protocol of obtaining samples 2, 4, 6, and 8 h after the morning feeding captured the diurnal 
variation in plasma Met concentrations and is adequate for determining the bioavailability of RP-
Met product.  
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Table 18. Effect of collection day on plasma Methionine concentration (µM) 
Treatment Day 5 Day 6 Day 7 SEM P-value 
CON 18.2 18.5 18.5 0.73 0.90 
INF-12 29.3 25.8 30.6 2.97 0.51 
INF-24 46.9 49.8 51.0 5.08 0.36 
RPM-15 34.3 37.8 35.5 2.57 0.76 




Table 19. Effect of collection times within day on plasma Met concentration (µM) (confidence 
interval) 
Treatment 2-8 h  10-16 h 18-24 h SEM P-value 
CON 18.3 (16.9-19.5) 18.0 (16.6-19.5) 18.9 (17.5-20.3) 0.73 0.57 
INF-12 28.1 (24.4-31.8) 28.8 (25.1-32.5) 30.4 (26.7-34.1) 1.91 0.83 
INF-24 50.1 (40.1-60.1) 48.6 (38.6-58.6) 51.2 (41.2-61.2) 5.12 0.51 
RPM-15 32.3 (29.2-35.4) 36.6 (33.5-39.7) 35.8 (32.7-38.9) 1.58 0.58 




Table 20. Estimates of bioavailability of rumen-protected Met 
 INF  RPM    
Item Slope SE  Slope SE Bioavailability 95% CI P-values
1 
2-8 h 1.36 0.145  1.15 0.038 84.7 78.8-90.6 0.001 
10-16 h 1.37 0.147  1.16 0.059 84.4 78.3-90.5 0.001 
18-24 h 1.33 0.120  1.20 0.038 90.0 83.7-96.3 0.001 
2-24 h 1.35 0.123  1.14 0.030 84.6 78.6-90.6 0.001 
1







Determination of relative methionine bioavailability in lactating cows fed Smartamine M, 
Mepron, and Aminoshure M using the plasma free amino acid dose-response method 
 
Introduction 
In vivo measurements of Met bioavailability in rumen-protected (RP)-Met supplements 
are critical to determine their contribution to metabolizable Met supply. The plasma free AA 
dose-response method has been proposed as a standardized method for determining 
bioavailability of AA in RP AA supplements This approach has already been used in several 
experiments to evaluate RP-Lys supplements (Whitehouse et al., 2011, 2014, 2015) and 1 
experiment to validate the applicability of the methodology for  RP-Met sources (Chirgwin et al., 
2015).  
Chirgwin et al. (2015) used the plasma free AA dose-response method to determine the 
bioavailability of Smartamine® M (Adisseo, Antony, France) to be 80.9 ± 0.4%. Devillard et al 
(2011) used the AUC method to determine the bioavailability for Smartamine M and Mepron. 
The bioavailability was 81% for Smaratmine M and 30% for Mepron. Faivre et al (2013) used 
the AUC method to determine the bioavailability for 4 RP-Met supplements. One of the RP-Met 
was AminoShure M and the bioavailability was determined to be 42.4 ± 6.5%.  
The objectives of this experiment were to use the plasma free AA dose-response method 
to determine bioavailability of Met in Smartamine® M from the new (SM1) and original (SM2) 
production plants and compare with Mepron® (MPN; Evonik Ind., Kennesaw, GA) and 
AminoShure®-M (ASM; Balchem Corp., New Hampton, NY). The hypothesis is that there will 
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be no difference between the 2 Smartamine M supplements since the only difference is the 
production plants and that the bioavailability for SM1 will be 80% and that from previous AUC 
work that AminoSure M will have a higher bioavailability than Mepron. 
Materials and Methods 
All procedures related to animal care were conducted with approval of the University of 
New Hampshire Institutional Animal Care and Use Committee (IACUC no. 150101). All 
experiments were conducted at the University of New Hampshire Fairchild Dairy Teaching and 
Research Center (Durham, NH). 
Experimental Design and Treatments 
Ten multiparous Holstein cows equipped with ruminal cannulas (Bar Diamond, Parma, 
ID) averaging (mean ± SD) 153 ± 40 DIM, 699 ± 57 kg of BW, and a 2.82 ± 0.30 BCS fed a 
Met-deficient basal diet, were assigned to a replicated 5 × 5 Latin square with 7-d experimental 
periods. A covariate period of 7 d prior to the start of the study was used as to obtain baseline 
milk production and plasma concentration of AA. The experimental treatments were: 1) 0 g/d of 
supplemental Met (CON), 2) 30 g/d of fed Met from SM1, 3) 30 g/d of fed Met from SM2, 4) 30 
g/d of fed Met from MPN, and 5) 30 g/d of fed Met from ASM. 
 The basal diet (Table 21) was fed 3 times daily at 0500, 1300, and 2100 h using a Super 
Data Ranger mixer (American Calan Inc., Northwood, NH). The RP-Met supplements were 
mixed with 1.5 kg of TMR, placed in a plastic container with a lid, and stored at 4°C for 8 h 
before feeding. This was done to take into account any potential effects of the TMR on the 
protective coatings of the RP-Met as reported by Ji et al. (2105). Next, the TMR/RP-Met mix 
was placed in rubber tubs and fed to the cows 30 min before each feeding to ensure complete 
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consumption. If the TMR/RP-Met mix was not consumed by the cow by the end of 30 min, it 
was top-dressed to the TMR offered to the cows. Treatments were not administered on d 1 of 
periods 2 to 5. For those periods, treatments were initiated on d 2. 
Management of Cows and Feed Collection and Analyses  
Cows were housed in a naturally ventilated tie-stall barn, fed individually and ad libitum 
with minimal orts (2 to 4%), and had access to water throughout the duration of the experiment. 
Cows were milked twice daily at 0430 and 1530 h with milk weights recorded at each milking. 
Samples of TMR and orts were collected daily and composited by equal weight in each period 
for determination of DM. The NRC (2001) evaluation of the consumed basal ration is shown in 
Table 21. 
Samples of corn and haycrop silages were collected daily throughout the study. 
AminoPlus , a heat treated soybean, (AG Processing Inc., Omaha, NE), fat, and vitamin-mineral 
mixes were collected weekly. The individual feedstuffs used to make the concentrate mix were 
sampled at the feed mill (Poulin Grain, Newport, VT) and sent to the University of New 
Hampshire Fairchild Dairy Teaching and Research Center. Ingredients were freeze-dried 
(Labconco Model 5, Kansas City, MO) for 48 h, stored in air-tight glass jars, and ground to pass 
through a 1-mm screen using a Wiley mill (Thomas Scientific; Arthur H. Thomas, Philadelphia, 
PA).  
Composites of each ingredient were shipped to a commercial laboratory (Dairy One 
Cooperative Inc., Ithaca, NY) for nutritional analyses according to the following methods: DM 
(method 930.15; AOAC, 2006), CP (method 990.03; AOAC, 2006), NDF [Ankom Technology 
method 6 (NDF in feeds-filter bag technique for A200; Ankom Technology, Fairport, NY); 
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solutions as in Van Soest et al., 1991], ADF [Ankom Technology method 5 (ADF in feeds-filter 
bag technique for A200; Ankom Technology); solutions as in method 973.18; AOAC, 1998], 
crude fat (method 2003.05; AOAC, 2006), and ash (method 942.05; AOAC, 2006). Feeds were 
also analyzed for AA concentration (cation-exchange chromatography coupled with post-column 
ninhydrin derivatization and quantitation method; method 982.30; AOAC, 2006; University of 
Missouri Experimental Station Chemical Laboratories, Columbia, MO). The chemical and AA 
composition of the feed ingredients is shown in Table 22. 
Samples of the SM1, SM2, MPN, and ASM were collected throughout the study and sent 
to Adisseo France to determine the concentration of Met using the Adisseo Method R693. 
Milk Sampling and Analyses  
  Milk samples were obtained from each cow during the p.m. and a.m. milkings on the last 
3 d of covariate and experimental periods. Samples were preserved in tubes containing 2-bromo-
2-nitropropan-1,3 diol (Broad Spectrum Microtabs II; Advanced Instruments, Inc., Norwood, 
MA), pooled by cow for each day according to daily milk weights, and refrigerated at 4°C until 
shipped to a commercial laboratory for determination of fat, true protein, lactose, and MUN by 
mid-infrared reflectance spectroscopy (method 972.16; AOAC, 2006; Dairy One Cooperative, 
Inc.). 
 
Blood Sampling and Analyses   
Blood samples were collected at 2, 4, 6, and 8 h after the morning feeding during the last 
3 d of the covariate and each experimental period and composited into 1 daily sample per cow 
for AA analyses. Blood was collected in 10-mL vacutainer tubes (Monoject, Mansfield, MA) 
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containing 15% EDTA vol/vol. Tubes were placed immediately on ice and centrifuged within 10 
to 15 min at 1,200 × g for 20 min at 4°C. A 4-mL aliquot of plasma from each sample was 
placed in a labeled glass test tube with 1.0 mL of 15% (wt/vol) 5-sulfosalicylic acid added to 
each tube. The tubes were allowed to sit for 10 min in the centrifuge before a second 
centrifugation (1,200 × g for 20 min at 5°C). An aliquot of 0.45 mL was removed, placed into 
1.8-mL cryovials, and stored at –80°C for AA analysis using norleucine as the internal standard 
and cation-exchange chromatography coupled with post-column ninhydrin derivatization and 
quantitation as done for the feedstuffs.  
Statistical Analyses  
The UNIVARIATE procedure of SAS (SAS version 9.4, Cary, NC) was used to 
determine outliers. An observation greater than 2.0 SD from the mean for Met and TSAA (i.e., 
Met + Cys-Cys + Cystathionine/Allocystathionine + Homocystine + Tau) was considered an 
outlier and removed from the dataset. The same approach for determination of outliers was used 
for milk yield and concentrations and yields of milk components. One day for a cow in the 
control treatment was considered an outlier and all her data for that day was removed from the 
analysis. During the SM1 treatment, a different cow became sick, her DMI decreased 16 kg/d 
and milk production deceased 20 kg/d, therefore, her data was not included in the final analysis. 
Data for DMI, milk yield, concentrations and yields of milk components, and plasma 
concentrations of AA were analyzed using the REPEATED procedure of SAS according to the 
following model: 
 Yijklm = μ + Li + Pj + Dk + Rl + LDik + βCijklm + Eijklm 
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where  Yijklm = is the dependent variable, μ = overall mean, Li = is the fixed effect of the i
th
  Met 
treatment, Pj = is the fixed effect of the j
th
 period, Dk = is the fixed effect of the k
th
 day, Rl = is 
the fixed effect of the l
th
 replicate, LDik = is the fixed effect of the interaction between the i
th
 
level of Met and the k
th
 day, β = is the regression coefficient of the covariate C, Cijklm = is the 
value of the covariate variable for the m
th
 cow within the k
th
 day of the i
th
 level of Met, and Eijklm 
= is the random residual ~N (0, 2e ). The random effect of cow (replicate) was used as the error 
term for the effect of day and day × level interaction. Degrees of freedom were calculated using 
the Kenward-Roger option of the MIXED procedure of SAS. Significance was noted at P ≤ 0.05 
and trends at P ≥ 0.05 to P ≤ 0.10. 
Day and day × level interactions were not significant. Therefore, the means for plasma 
AA concentration and milk parameters were calculated and analyzed using the PROC MIXED 
procedure of SAS according to the following model: 
Yijkl = μ + Li + Pj + Rk + βCijlm + Eijkl 
where  Yijk = is the dependent variable, μ = overall mean, Li = is the fixed effect of the i
th
 level of 
Met, Pj =is the fixed effect of the j
th
 period, Rk = is the fixed effect of the k
th
 replicate, β = is the 
regression coefficient of the covariate C, Cijkl = is the value of the covariate variable for the l
th
 
cow within the i
th
 level of Met, and Eijkl = is the random residual ~N (0,
2
e ). The random effect 
of cow (replicate) was used as the error term. Degrees of freedom were calculated using the 
Kenward-Roger option of the MIXED procedure of SAS. Significance was noted at P ≤ 0.05 and 
trends at P ≥ 0.05 to P ≤ 0.10. Treatment effects were determined using the CONTRAST 
statement of SAS. The PDIFF option of SAS was used to separate least square means. 
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Least square means were calculated as plasma concentration of TSAA expressed as a 
percentage of the total plasma concentration of AA subtracted from TSAA concentration. The 
plasma concentration of total AA was determined by the sum of the following AA: Arg, His, Ile, 
Leu, Lys, Met, Phe, Thr, Trp, Val, Ala, Asn, Asp, Cit, Cys, cystathionine/allocystathionine, Gln, 
Glu, Gly, homocysteine, Orn, Pro, Ser, Tau, and Tyr. In addition, least square means were 
subjected to the REG procedure of SAS to generate the regression coefficients, slopes, and r
2
 
using the slope ratio assay (Finney, 1978).  
Relative bioavailability of was determined using the following equation:   
Relative bioavailability = slope of the RP-Met supplement / slope of the SM2 supplement 
Results and Discussion 
 The concentration of Met in the 4 RP-Met supplements is reported in Table 23. For SM1, 
SM2, and ASM, the amount of measured Met in the supplements was slightly greater than the 
manufacturer’s guaranteed Met concentration, whereas for MPN the measured Met was lower 
than the guaranteed Met analysis. Therefore, the actual amount of Met fed herein was 
recalculated and the resulting values were 30.2, 30.3, 29.1, and 30.3 g/d of Met for SM1, SM2, 
MPN, and ASM, respectively. 
Lactational performance and DMI are presented in Table 24. There were no effects of 
treatment on DMI, milk yield, 4% FCM, ECM, concentration and yield of milk fat, yields of 
milk true protein and lactose, concentration of MUN, and feed efficiency. However, milk protein 
concentration was greater for cows fed SM1 and SM2 compared to those fed CON and ASM (P 
= 0.02). There was no difference between MPN and the other 4 treatments. The increase in milk 
true protein concentration confirmed that a Met deficient diet was fed. Schwab et al. (1992a), 
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Rulquin et al. (1993), and Pisulewski et al. (1996) fed Met deficient diets and observed increases 
in milk true protein concentration as the amount of Met infused increased. Rulquin and Delaby 
(1997), Chen et al. (2011), and Zang et al. (2016) fed Smartamine M and observed increases in 
milk true protein concentrations. Milk lactose concentration was lower (P = 0.04) for cows fed 
SM1 and SM2 compared to those offered CON and ASM, but no difference between MPN and 
the other treatments was observed. Chen et al. (2011) and Zang et al. (2016) observed no effect 
on milk lactose concentration, while a decrease was reported by Čermakova et al. (2012). 
Leonardi et al. (2003) and Broderick et al. (2009) fed MPN and observed an increase in milk true 
protein concentration with no effect on that of lactose. For MPN we also observed no effect on 
lactose concentrations. Ardalan et al. (2016) observed increases in milk true protein 
concentrations when both Smartamine M and MPN were fed, and stated there was no difference 
between these 2 RP-Met supplements in their ability to increase milk true protein concentration. 
Arriola Apelo et al. (2014) observed no effect on milk protein and lactose concentrations when 
ASM was fed, while Barnard et al. (2016) did observe a protein concentration response, when 
AminoShureM was fed to deliver 22.5 g/d of Met. In the present trial ASM was fed to deliever 
30 g/d of Met and we observed no responses to milk true protein concentration. These 
differences may be due to the protein content of the diets, Arriola Apelo et al. (2014) fed a 
15.2% CP diet, while the present trial a 16.4% CP diet was fed, while the CP of the diet for 
Barnard et al. (2016) was not reported. 
Plasma concentrations of AA are reported in Table 25. There were no significant effects 
of treatments on plasma concentrations of Arg, Lys, Phe, Thr, Asn, Asp, Cit, Glu, homocysteine, 
Orn, Pro, EAA, and urea-cycle AA. Trends were observed for decease in plasma concentrations 
of Ala, NEAA, and total AA (P = 0.06) and Tyr (P = 0.09) for all treatments compared to CON.  
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Plasma concentrations of Met and Tau were lower for CON compared to the RPAA 
treatments, with SM1 and SM2 being greater than MPN and ASM (P < 0.0001). Plasma 
concentrations of Cys were lower for CON compared to SM1, SM2, and MPN (P = 0.001). 
Plasma concentrations of cystathionine/allocystathionine and total sulfur AA were greater for 
SM1 and SM2 compared to the other treatments (P < 0.0001). All of the sulfur AA except 
homocysteine increased in varying degrees with the addition of RP-Met to the diet. Patton et al. 
(2015) reported increase in plasma Met concentrations with supplemental Met. Blum et al. 
(1998) observed an increase in plasma concentrations of Met, Cys, and Tau. Ardalan et al. 
(2016) and Zang et al. (2016) also observed increases in plasma concentrations of Met, with 
Smartamine M showing greater concentrations than Mepron, which corroborate results from the 
current study.  
Plasma concentration of His was lower for SM1 and ASM compared to CON (P = 0.03).  
For dairy cows fed diets containing predominantly corn and soy ingredients, His may be the third 
limiting AA (NRC, 2001). Therefore, meeting the Met requirements may increase the utilization 
of the third limiting AA for increased protein synthesis which maybe His in this study. However, 
this does not explain why Lys, expected to be the second limiting AA, did not decrease in plasma 
concentration in concert with His. Giallongo et al. (2016) also fed a diet containing 
predominantly corn and soy ingredients and reported decreased plasma His concentrations when 
Met and Lys were considered adequate in the diet. Histidine along with Ala, which tended to 
decrease, are involved in the formation of carnosine, which can act as an antioxidant in the body 
(Nelson and Cox, 2008). 
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Plasma concentration of Ile was lower for SM1, SM2, and ASM compared to CON (P = 
0.05). Plasma concentrations of Leu and total BCAA were lower for all RPAA treatments 
compared to CON (P = 0.004). Plasma concentration of Val were greater for CON compared to 
the RPAA treatments, with SM1 being lower than MPN and ASM (P = 0.002). A possible 
explanation for the decreases in plasma concentrations of BCAA may be due to an increase in 
globular proteins in milk. The BCAA are involved in globular protein formation (Brosnan and 
Brosnan, 2006). For instance, whey protein is comprised of globular proteins, primarily as 
lactoglobulin (Fox et al., 2015). The BCAA also donate their amino group for the synthesis of 
Ala (Wu et al., 2014). In the current study, the plasma concentration of Ala did not differ 
significantly among treatments. Blum et al. (1999) reported decreases in the plasma 
concentrations of Ile and Val, with no effect on Leu when Smartamine M was fed. Blum et al. 
(1999) reported no effect on plasma Ile, Leu, and Val when MPNwas fed, unlike data from the 
present study. Blum et al. (1999) fed the RP-Met once a day, blood samples were taken 1 d at 
2.5, 6.5, and 10.5 h after feeding, while in the present study the RP-Met wase fed 3 times and 
samples are taken for 3 d at 2, 4, 6, and 8 h after feeding, this may have allowed the present 
study to pick up the changes in plasma BCAA concentrations. Patton et al. (2015) conducted a 
meta-analysis on circulating plasma concentrations and duodenal flows of AA in lactating dairy 
cows and reported decreases in Ile, Leu, and Val when Met was infused as DL-Met or fed as RP-
Met. 
Plasma concentration of Trp was lower for ASM compared to CON and SM2, but did not 
differ from SM1 and MPN (P = 0.04). Tryptophan is essential for the production of nicotinic 
acid which is found in NAD and NADP, both important in metabolic reactions that supply 
energy (Nelson and Cox, 2008). The increased milk protein synthesis requires energy that can 
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come for NADPH (Fox et al., 2015). Since ASM did not increase milk protein concentration or 
yield, this is not the reason for the decrease in Trp and Arriola Apelo et al. (2014) did not 
measure Trp in their study.  
Plasma concentrations of Gln and Gly were lower for SM1 compared to CON, MPN, and 
ASM (P = 0.001). Glycine and Gln are involved in the formation of glutathione (Nelson and 
Cox, 2008). Zhou et al. (2016) observed greater concentrations of glutathione in the liver of cows 
fed Smartamine M 21 d before calving. In this study, glutathione was not measured, but there 
were observed decreases in Gly and Gln.  
Plasma concentrations of Ser were lower for SM2 compared to the other 4 treatments and 
SM1 was lower than CON (P = 0.001). Serine is involved in formation of phospholipids and in 
the methylation of RNA and DNA in the trans-sulfuration pathway (Nelson and Cox, 2008). 
With the increase in milk protein, there is an increase in DNA for the synthesis of milk protein 
and this may cause the decrease in Ser. Pisulewski et al. (1996) also observed a decrease in Ser 
when milk true protein concentration and yield increased. 
The bioavailability of Met in SM2 has been reported to be 80% (Rulquin and Kowalczk, 
2003; Chirgwin et al., 2015) and was chosen as the positive control in this trial instead of 
infusion. Therefore, the calculated bioavailability of SM1, MPN, and ASM relative to SM2 was 
79.6, 22.5, and 17.2%, respectively (Figure 20). Therefore, the amount of MP-Met provided per 
gram of Met per kilogram of supplement was 628, 608, 189, and 127 g/kg for SM2, SM1, MPN, 
and ASM, respectively (Table 3; Figures 20 and 21). Bioavailability for MPN and ASM has been 
determined using the mobile bag and plasma area-under-the-curve (AUC) methods. Using AUC, 
Devillard et al. (2011) determined the bioavailability of Met in MPN to be 30%. Koenig and 
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Rode (2001) also conducted an experiment using the AUC methodology for MPN and reported a 
28% bioavailability. Faivre et al. (2013) using the AUC determined the bioavailability of ASM 
to be 42%. The AUC method uses ruminally cannulated cows with jugular catheters. Blood 
samples are taken before treatment for baseline measurements and then a spot dose of the RPAA 
is placed into the rumen and blood samples are collected up to 72 h.  The elemental trapezoidal 
AUC were calculated by multiplying the mean of the Met increases 
between 2 consecutive times of sampling and the duration of the interval between the samplings 
to determine the bioavailabilities (Graulet et al., 2005) Using the mobile bag method, Overton et 
al. (1996) determined the bioavailability of MPN to be 57%, Berthiaume et al. (2000) reported a 
48% bioavailability, and Koenig and Rode (2001) reported a bioavailability 25%. All of these 
bioavailabilities reported for MPNusing the mobile bag method used 6 h incubation in the 
rumen. However, if the incubation in the rumen increases, then the rumen protection decreases 
and the bioavailability decreases. Arriola Apelo (2014) used the mobile bag method to determine 
the bioavailability of ASM to be 31%. The mobile bag method uses ruminally and duodenally 
cannulated cows. A rumen protection rate is determined by incubating the RPAA in bags placed 
in the rumen for a specified time and the amount of RPAA that remains in the bag is determined. 
The RPAA is then incubated in an acid solution to simulate the abomasum and then placed into 
the duodenum via the duodenal cannula. Bags are then collected in the feces and the amount of 
AA that disappeared form the bags is determined (Overton et al., 1996; Berthiaume et al., 2000; 
Koenig and Rode, 2001). 
Conclusions 
 The amount of Met supplied in SM1 and SM2 were not different from each other. For 
ASM the bioavailability of 17% that was determined in the present study was lower than what 
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has been previously determined with the mobile bag method. For MPN the bioavailability of 
22% that was determined in the present study is lower than what has been reported with the 
mobile bag method, but  similar to what the AUC reports for a bioavailability. SM1 and SM2 




Table 21. Ingredient and chemical composition of the basal diet infused with Met or 
supplemented with rumen-protected Met 
Ingredient, % of DM  
Corn silage, mature 34.7 
Mixed mostly grass silage, mid-maturity 15.9 
Steam flaked corn 4.56 
Corn meal 11.86 
Soy hulls 3.65 










Mineral/vitamin mix 3.04 








NEL balance, Mcal/kg 1.3 
RDP balance, g/d 37 
RUP balance, g/d 103 
MP-Lys, % MP 6.58 
MP-Met, % MP 1.78 
MP-Lys, g/d 199 
MP-Met, g/d 54 
1 
AG Processing Inc (Omaha, NE). 
2
Berg + Schmidt America LLC, (Libertyville, Il). 
3






Table 22. Chemical and AA composition of feedstuffs (% of DM unless otherwise noted) fed to Holstein cows infused with Met or 






























DM 30.7 33.5 90.4 93.1 91.7 89.5 92.1 93.6 76.4 99.5 99.6 99.1 
CP 7.3 17.7 8.4 39.8 6.8 6.8 49.5 10.9 8.4 283.9 - - 
aNDFom 41.7 45.5 9.7 26.0 21.8 7.5 21.1 64.5 - - - - 
ADF 27.0 33.2 2.7 20.2 19.8 2.4 10.4 47.2 - - - - 
NDF-CP 0.7 3.2 1.0 6.1 2.6 1.0 16.7 3.8 - - - - 
ADF-CP 0.5 1.2 0.3 2.5 0.7 0.5 0.8 0.9 - - - - 
Lignin 2.9 6.0 0.8 9.0 1.7 1.0 0.6 2.1 - - - - 
NFC 43.1 19.2 76.1 23.0 60.0 82.8 20.7 17.6 - - - - 
Starch 34.6 1.3 70.4 1.4 6.3 75.8 0.2 0.6 - - - - 
Ether extract 3.9 7.6 3.7 4.2 3.8 2.0 1.3 1.8 1.8 - 99.9 - 
Ash 4.05 10.06 2.01 7.00 7.55 1.00 7.46 5.16 15.12 - - - 
Ca 0.22 0.65 0.02 0.61 1.59 0.01 0.45 0.56 1.09 - - 12.28 
P 0.23 0.34 0.34 1.01 0.12 0.18 0.63 0.11 0.07 - - 1.63 
Mg 0.10 0.25 0.12 0.53 0.15 0.06 0.28 0.24 0.43 - - 4.53 
K 0.87 2.47 0.42 1.16 0.80 0.24 2.18 1.22 5.00 - - 0.39 
Na 0.004 0.078 0.002 0.047 0.210 0.001 0.002 0.001 0.087 - - 9.281 
Cl 0.22 0.82 0.07 0.11 0.13 0.09 0.13 0.12 - - - 7.61 
Fe (ppm) 199 283 31 175 77 15 118 399 144 - - 3450 
Zn (ppm) 23 25 22 55 20 11 43 40 13 - - 1420 
Cu (ppm) 5 9 2 5 8 1 13 6 12 - - 866 
Mn (ppm) 11 57 7 56 17 2 34 14 11 - - 791 
S 0.11 0.28 0.10 0.69 0.11 0.09 0.38 0.12 1.03 - - 0.50 
Arg, %CP 1.67 2.50 4.02 6.32 3.98 3.85 6.62 5.37 0.16 - - - 
His, %CP 1.52 2.05 3.01 3.17 2.23 3.39 2.76 3.07 0.47 - - - 
Ile, %CP 3.64 4.36 3.14 4.35 3.51 3.70 4.50 4.70 0.78 - - - 






Lys, %CP 3.03 5.26 3.64 6.37 3.51 3.54 6.10 7.96 0.62 - - - 
Met, %CP 1.82 1.60 1.63 2.11 1.27 2.00 1.32 1.25 0.31 - - - 
Phe, %CP 3.79 4.68 4.14 4.21 4.14 5.08 4.74 4.31 0.47 - - - 
Thr, %CP 3.18 4.04 3.14 4.48 3.51 3.54 3.66 4.03 1.09 - - - 
Trp, %CP 0.45 0.58 0.75 1.25 1.12 0.92 1.36 0.86 0.31 - - - 
Val, %CP 5.15 5.71 4.52 5.79 4.78 5.24 4.98 5.37 1.87 - - - 
1 








Table 23. Methionine concentrations of RP-Met supplements
1 
 
SM1 SM2 MPN ASM 
n
2 7 7 2 2 
Mean  76.54 78.47 83.9 73.95 
SD 0.41 0.40 0.57 0.21 
Lot# ----- 121514001C1 260714-01 14135 
 
1
 SM1 = Smartamine M from the new production facility. SM2 = Smartamine M from the 
original production facility. MPN = Mepron. ASM = AminoShure-M. 
2
 number of samples analyzed. 
  





Table 24.  Lactational performance for cows supplemented with RP-Met supplements 
Item CON SM1 SM2 MPN ASM SEM P-value 
Milk yield, kg/d 46.2 46.6 46.5 45.0 45.8 1.03 0.60 
DMI, kg/d 27.5 27.3 27.5 27.1 27.4 0.56 0.93 
Milk fat, %    3.59 3.57 3.61 3.58 3.65 0.11 0.95 
Milk fat, kg/d 1.65 1.66 1.68 1.61 1.66 0.63 0.63 











Milk true protein, kg/d 1.32 139 1.39 1.31 1.32 0.37 0.08 











Milk lactose, kg/d 2.26 2.25 2.25 2.18 2.21 0.54 0.64 
MUN, mg/dL 13.7 12.8 12.7 12.9 12.8 0.49 0.50 
4% FCM, kg/d
1 
46.8 47.2 47.5 45.5 46.7 1.32 0.48 
ECM, kg/d
2 
46.2 47.0 47.3 45.1 46.1 1.27 0.33 
Milk yield/DMI, kg/kg 1.69 1.72 1.70 1.68 1.68 0.028 0.81 
1
 4% FCM = (0.4255 × milk yield, kg) + (16.425 × (milk yield, kg × fat, %)) 
2
 ECM = (0.192 + (fat, % × 0.0929) + (protein, % × 0.0563)) × (milk yield, kg / 0.68605) 
  





Table 25. Plasma amino acids (µM) in Holstein cows fed a Met deficient diet supplemented with rumen-protected  
Met supplements 
Item CON SM1 SM2 MPN ASM SEM     P-value 














































Phe 53.0 51.8 51.7 51.5
 
51.0 0.94 0.39 























Ala 281.3 270.3 280.2 267.5 258.0 9.94 0.06 
Asn 57.7 54.8 57.3 56.7 55.1 1.94 0.31 
Asp 4.85 4.57 4.40 4.81 4.82 0.357 0.70 














































Homocystine 1.37 1.57 1.46 1.46 1.48 0.069 0.37 
Orn 57.1 56.1 60.4 58.6 55.8 1.92 0.12 























Tyr 55.5 50.9 53.0 53.0 52.7 1.54 0.09 
Total EAA 1199 1158 1193 1176 1157 35.6 0.18 
Total NEAA 1358 1293 1334 1341 1296 32.0 0.06 
Total  AA 2557 2451 2527 2517 2453 54.7 0.06 
Total branched chain AA
1








672 22.9 0.004 
Total urea cycle AA
2
 2578 252 261 257 245 7.6 0.56 



















 Total branched chain AA = Ile + Leu + Val 
2
 Total urea cycle AA = Arg + Cit + Orn 
3







   
 
Figure 20. Response of plasma Met concentrations (%TAA) to graded levels of SM2 (■), SM1 
(♦), MPN (▲), and ASM (●) in lactating dairy cows fed a Met deficient diet. Equations for SM2 
[Y = 3.88 +0.070x; SE slope = 0.004, SE intercept = 0.09, R
2
 = 0.99, RMSE = 0.14] assumed to 
have a 80% bioavailability, SM1 [Y = 3.88 +0.070x; SE slope = 0.004, SE intercept = 0.09, R
2
 = 
0.99, RMSE = 0.15] the calculated bioavailability was 79.6%, MPN [Y = 3.88 +0.0.20x; SE 
slope = 0.004, SE intercept = 0.09, R
2
 = 0.84, RMSE = 0.15] the calculated bioavailability was 
22.3%, and ASM [Y = 3.88 +0.015x; SE slope = 0.005, SE intercept = 0.11, R
2
 = 0.69, RMSE = 





Figure 21. Relative Met bioavailability of the RP-Met supplements. 80% Met bioavailability for 
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